



Curriculum Vitae

Personal information **Eolia BRISSOT**

Work experience

Chef de Clinique-assistant , University Hospital of Nantes and University Hospital SaintAntoine, Paris 2005-2010
Chef de Clinique-assistant, Service d'hématologie, Sorbonne University Hospital Saint-Antoine, 2014-2016
Associate Professor, Service d'hématologie, Sorbonne University Hospital Saint-Antoine, Paris, 2016-current
Secretary of the Acute Leukemia Working Party of EBMT, European Society for Blood and Marrow Transplantation 2022
Professor, service d'hématologie, Sorbonne University Hospital Saint-Antoine, Paris, 2024

Education and training

Sorbonne University PhD - « Involvement of the CX3CL1 (fractalkine)/CX3CR1 pathway in the pathogenesis of acute graft-versus-host disease» , 2014
Paris Cité, Degree " Metavers in Health", 2023
University of Nantes, MASTER 2- in "Biology Biotechnology Research Therapy, 2010
Medical Doctor Degree, 2012
Hematology specialist Degree, 2012
University of Lyon, France 2009
Institut Gustave-Roussy and hospital of Créteil, France, 2008
University of Rennes, France, 2001
MASTER « Molecular biology of the cell », 2000

Additional information

Publications

05 peer-reviewed articles :

- 1: Nagler A, Kayser S, Ferhat AT, Kröger N, Eder M, Socié G, Blaise D, Schroeder T, Labussière-Wallet H, Maertens J, Busca A, Forcade E, Gedde-Dahl T, Rambaldi A, Bulabois CE, Bug G, Bazarbachi A, Brissot E, Savani B, Mohty M, Ciceri F. Non-T-Depleted Haploidentical Transplantation Compared to Allogeneic Transplantation From Matched Siblings or Unrelated Donors in Patients With Secondary AML in First Complete Remission: A Study From the ALWP/EBMT. *Am J Hematol*. 2025 Dec 6. doi: 10.1002/ajh.70164. Epub ahead of print. PMID: 41351865.
- 2: Bazarbachi A, Galimard JE, Abou Dalle I, Labopin M, Sanz J, Huang H, Mayer J, Solano C, Lioure B, Griskevicius L, Maertens J, Itälä-Remes M, Kaare A, Gallego-Hernanz MP, Bug G, Ribera JM, Gadisseur A, Schmid C, Kwon M, Poiré X, Coccia P, Jurado Chacón M, Baron F, Craddock C, Brissot E, Nagler A, Ciceri F, Mohty M. Frequency and impact of somatic co-occurring mutations on post-transplant outcomes in acute myeloid leukemia: a multicenter registry analysis on behalf of the EBMT ALWP. *Bone Marrow Transplant*. 2025 Dec 5. doi: 10.1038/s41409-025-02770-4. Epub ahead of print. PMID: 41345260.
- 3: Belkacemi Y, Debbi K, To NH, Tour RP, Quero L, Balsat M, Martel-Lafay I, Beauvais D, Mirabel X, Forcade E, Batard S, Devillier R, Gonzague-Casabianca L, Chevallier P, Guimas V, Brissot E, Maertens J, Poiré X, Ceballos P, Llorente CC, Bilger K, Bulabois CE, Cherif AM, Coraggio G, Quoc SN, Robin M, Loganadane G. Total Body Irradiation-Based Versus Chemotherapy-Alone Myeloablative Conditioning Regimen Before Hematopoietic Allogeneic Stem Cell Transplantation in Adults With Acute Lymphoblastic Leukemia: A Multi-Institutional Study From the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC). *Int J Radiat Oncol Biol Phys*. 2025 Oct 22:S0360-3016(25)06389-8. doi: 10.1016/j.ijrobp.2025.10.003. Epub ahead of print. PMID: 41135711.
- 4: Nagler A, Esteve J, Galimard JE, Sanz J, Poire X, Collin M, Maertens J, Huang H, Itälä-Remes M, Halahleh K, Pascual Cascon MJ, Chiusolo P, Griskevicius L, Kaare A, De Becker A, Jindra P, Pérez-Simón JA, Bazarbachi A, Brissot E, Ciceri F, Mohty M. Impact of Wilms' tumor 1 gene (WT1) mutation on outcome of allogeneic hematopoietic-cell transplantation for acute myeloid leukemia: a retrospective multicenter cohort study from the ALWP/EBMT registry. *Bone Marrow Transplant*. 2025 Oct 16. doi: 10.1038/s41409-025-02727-7. Epub ahead of print. PMID: 41102401.
- 5: Pochon C, Rabian F, Brissot E, Chauvet P, Olivier L, Magro L, Dourthe ME. Choix du traitement précédant la réinjection des cellules CAR-T autologues en

traitement des leucémies aiguës lymphoblastiques de phénotype B des patients de 0 à 25 ans (SFGM-TC) [Choice of bridging therapy prior to reinjection of autologous CAR-T cells in patients aged 0-25 years treated for B-ALL (SFGM-TC)]. *Bull Cancer*. 2025 Sep 19;S0007-4551(25)00389-3. French. doi: 10.1016/j.bulcan.2025.07.016. Epub ahead of print. PMID: 40975678.

6: Jullien M, Brissot E, Daguindau E, Loschi M, Bazarbachi A, Labussiere-Wallet H, Huynh A, Schmidt-Tanguy A, Charbonnier A, Turlure P, Beckerich F, Devillier R, Bay JO, Srour M, Ceballos P, Alani M, Souchet L, Marchand T, Rubio MT, Forcade E, Cornillon J, Chantepie S, Bulabois CE, Villate A, Garnier A, Peterlin P, Le Bourgeois A, Guillaume T, Chevallier P; Société Francophone de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC). Thiotepa-busulfan-fludarabine compared to clofarabine-based conditioning for haploidentical transplant with posttransplant cyclophosphamide in patients with myeloid malignancies: a retrospective study from the SFGM-TC. *Bone Marrow Transplant*. 2025 Dec;60(12):1592-1600. doi: 10.1038/s41409-025-02709-9. Epub 2025 Sep 15. PMID: 40954245.

7: Gras E, Monzo-Gallo P, Azoyan L, Garcia-Vidal C, Lanternier F, Brissot E, Guitard J, Lacombe K, Dechartres A, Surgers L. Risk factors for invasive fungal infections in adult patients with hematological malignancies and/or stem cell transplant: a systematic review and meta-analysis. *Sci Rep*. 2025 Aug 21;15(1):30724. doi: 10.1038/s41598-025-16066-6. PMID: 40841820; PMCID: PMC12371109.

8: Sanz J, Ferhat AT, Kulagin A, Kröger N, Rovira M, Lazzari L, Arat M, Montoro J, Versluis J, Reményi P, Sica S, Blaise D, Saif MA, Vydra J, Fagioli F, Nur E, Giebel S, Peric Z, Brissot E, Nagler A, Piemontese S, Mohty M, Ciceri F. Selection of unrelated donors for allogeneic transplantation using post-transplant cyclophosphamide in acute lymphoblastic leukemia: An analysis by the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. *Haematologica*. 2025 Jul 31. doi: 10.3324/haematol.2025.287750. Epub ahead of print. PMID: 40820728.

9: Gras E, Azoyan L, Monzo-Gallo P, Garcia-Vidal C, Lanternier F, Brissot E, Guitard J, Lacombe K, Dechartres A, Surgers L. Risk factors for invasive mould infections in adult patients with hematological malignancies and/or stem cell transplant: A systematic literature review and meta-analysis. *J Infect*. 2025 Sep;91(3):106574. doi: 10.1016/j.jinf.2025.106574. Epub 2025 Aug 11. PMID: 40803450.

10: Ye Y, Labopin M, Yakoub-Agha I, Socié G, Blaise D, Gedde-Dahl T, Blau IW, Raiola AM, Byrne J, Daguindau E, Labussière-Wallet H, Huynh A, Bazarbachi A, Nagler A, Brissot E, Li L, Luo Y, Shi J, Mohty M, Huang H, Ciceri F. Superior GVHD-Free, Relapse-Free Survival for Haploidentical Transplant With PTCy Than Matched Unrelated Donor for AML Patients Transplanted in Second Complete Remission: A Study From the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. *Am J Hematol*. 2025 Oct;100(10):1760-1771. doi: 10.1002/ajh.70008. Epub 2025 Jul 12. PMID: 40650544.

11: Li L, Ye Y, Galimard JE, Labopin M, Wu D, Chen J, Kröger N, Passweg J, Salmenniemi U, Itälä-Remes M, Poiré X, Eder M, Maertens J, Burns D, Sengeloev H, Olesen G, Blaise D, Finke J, Gadisseur A, Bazarbachi A, Brissot E, Nagler A, Luo Y, Shi J, Mohty M, Huang H, Ciceri F, Claude Gorin N Sr. <i>TET2</i> mutation does not impact the prognosis of adult acute myeloid leukemia patients receiving a hematopoietic stem cell transplantation in first remission: similar outcome following matched sibling and unrelated <i>versus</i> haploidentical donor transplants in a multi-center retrospective analysis from the Global Committee and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. *Haematologica*. 2025 Dec 1;110(12):3088-3093. doi: 10.3324/haematol.2025.287326. Epub 2025 Jun 19. PMID: 40534491; PMCID: PMC12666293.

12: Bazarbachi A, Galimard JE, Dalle IA, Socié G, Versluis J, Wu D, Eder M, Labussière-Wallet H, Yakoub-Agha I, Maertens J, Forcade E, Gedde-Dahl T, Choi G, Castilla-Llorente C, Baron F, Brissot E, Esteve J, Nagler A, Mohty M, Ciceri F. Challenging the Adverse Label: Diverse Outcomes of ELN 2022 Adverse Cytogenetic Subgroups in Acute Myeloid Leukemia Patients Allografted in First Remission: From EBMT ALWP. *Am J Hematol*. 2025 Aug;100(8):1374-1386. doi: 10.1002/ajh.27726. Epub 2025 May 30. PMID: 40445901.

13: Moukalled N, Ferhat AT, Bazarbachi A, Blaise D, Broers AEC, Castilla-Llorente C, Wagner-Drouet E, Halkes C, Schroeder T, Passweg J, Yakoub-Agha I, Dreger P, Kröger N, Fanin R, Gabellier L, Blau IW, Brissot E, Nagler A, Giebel S, Mohty M, Ciceri F. Improved outcomes over time in patients aged ≥60 years undergoing allogeneic hematopoietic cell transplantation for acute lymphoblastic leukemia in first complete remission: a large study by the EBMT acute leukemia working party. *Bone Marrow Transplant*. 2025 Aug;60(8):1160-1168. doi: 10.1038/s41409-025-02630-1. Epub 2025 May 28. PMID: 40437045.

14: Chalandon Y, Devillier R, Boumendil A, Nguyen S, Bulabois CE, Ceballos P, Brissot E, Rubio MT, Labussière-Wallet H, Maertens J, Chevallier P, Maillard N, Poiré X, Castilla-Llorente C, Beguin Y, Cornillon J, Maury S, Marchand T, Daguindau E, Bay JO, Turlure P, Joris M, Menard AL, Bilger K, Guillerm G, François S, Bazarbachi A, Chantepie S, Lewalle P, Marçais A, Loschi M, Benakli M, Chauvet P, Forcade E, Huynh A, Robin M, Masouridi-Levrat S. Allogeneic Hematopoietic Stem Cell Transplantation for Elderly Acute Lymphoblastic Leukemia Patients: A Registry Study From the Société Francophone de Greffe de Moelle et Thérapie Cellulaire (SFGM-TC). *Am J Hematol*. 2025 Jul;100(7):1173-1184. doi: 10.1002/ajh.27701. Epub 2025 May 6. PMID: 40326583.

15: Tarantino S, Labopin M, Zeiser R, Stelljes M, Schroeder T, Kröger N, Bethge W, Passweg J, Bornhäuser M, Schmid C, Tischer J, Eder M, Brissot E, Esteve J, Nagler A, Mohty M, Ciceri F. Allogeneic stem cell transplantation in de novo core-binding factor acute myeloid leukemia in active disease: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. *Bone Marrow Transplant*. 2025 Jul;60(7):1027-1035. doi: 10.1038/s41409-025-02596-0. Epub 2025 Apr 23. PMID: 40269277.

16: Larue M, Malard F, Alaskar AS, Aljurf M, Arat M, Balsat M, Baron F, Basak G,

Bazarbachi A, Bonifazi F, Brissot E, Ciceri F, Corbacioglu S, Dignan F, Huynh A, Kenyon M, Kuball J, Lachance S, Masszi T, Nagler A, Okamoto S, Pagliuca A, Ruggeri A, Ruutu T, Yakoub-Agha I, Ye Y, Duarte RF, Perić Z, Carreras E, Mohty M. Management of liver sinusoidal obstruction syndrome/veno-occlusive disease in adults: a 2025 perspective from an international expert group. *Bone Marrow Transplant.* 2025 Jul;60(7):1002-1008. doi: 10.1038/s41409-025-02598-y. Epub 2025 Apr 22. PMID: 40263636.

17: Chevallier P, Thiebaut A, François S, Chantepie S, Rubio MT, Labussiere-Wallet H, Brissot E, Maillard N, Huynh A, Coiteux V, Jullien M, Garnier A, Le Bourgeois A, Peterlin P, Guillaume T. A phase II study of ponatinib for prevention of relapse after allogeneic transplantation in *FLT3* internal tandem duplication mutation-positive (*FLT3*-ITD⁺) acute myeloid leukemia: the PONALLO trial. *Haematologica.* 2025 Oct 1;110(10):2525-2529. doi: 10.3324/haematol.2025.287681. Epub 2025 Apr 17. PMID: 40241541; PMCID: PMC12485311.

18: Abou Dalle I, Labopin M, Khvedelidze I, Baron F, Brissot E, Bug G, Esteve J, Giebel S, Gorin NC, Lanza F, Nagler A, Peric Z, Piemontese S, Ruggeri A, Sanz J, Savani B, Schmid C, Shouval R, Spyridonidis A, Versluis J, Ciceri F, Bazarbachi A, Mohty M. Growing adoption of pharmacologic maintenance therapy after allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a survey on behalf of the EBMT acute leukemia working party. *Bone Marrow Transplant.* 2025 Jun;60(6):921-923. doi: 10.1038/s41409-025-02576-4. Epub 2025 Apr 15. PMID: 40229537.

19: Bazarbachi A, Labopin M, Dalle IA, Yakoub-Agha I, Socié G, Schroeder T, Blaise D, Poiré X, Balsat M, Salmenniemi U, Kröger N, Kulagin A, Wagner-Drouet EM, Wu D, Brissot E, Nagler A, Giebel S, Ciceri F, Mohty M. Improved post-transplant outcomes since 2000 for Ph-positive acute lymphoblastic leukemia in first remission: A study from the EBMT Acute Leukemia Working Party. *Hemasphere.* 2025 Apr 13;9(4):e70117. doi: 10.1002/hem3.70117. PMID: 40224161; PMCID: PMC11993932.

20: Ye Y, Berland ATF, Labopin M, Chen J, Wu D, Blaise D, Di Grazia C, Forcade E, Huang XJ, Yakoub-Agha I, Salmenniemi U, Chevallier P, Bazarbachi A, Nagler A, Brissot E, Li L, Luo Y, Zhao Y, Mohty M, Huang H, Ciceri F, Gorin NC. Better Outcome Following Younger Haploidentical Donor Versus Older Matched Unrelated Donor Transplant for Fit Patients With Acute Myeloid Leukemia Transplanted in First Remission: A Study From the Global Committee and the Acute Leukemia Working Party of the EBMT. *Am J Hematol.* 2025 Jul;100(7):1252-1255. doi: 10.1002/ajh.27681. Epub 2025 Apr 7. PMID: 40192085.

21: Sanz J, Labopin M, Versluis J, Blaise D, Lazzari L, Montoro J, Van Gorkom G, von dem Borne P, Sandrine L, Rovira M, Reményi P, Chevallier P, Kwon M, Eder M, Vydra J, Brissot E, Spyridonidis A, Piemontese S, Mohty M, Ciceri F. Cytogenetic and molecular risk-driven conditioning intensity in acute myeloid leukemia patients undergoing stem cell transplantation with post-transplant cyclophosphamide: a study from the acute leukemia working party of the EBMT. *Bone Marrow Transplant.* 2025 Apr;60(4):529-534. doi: 10.1038/s41409-025-02527-z. Epub 2025 Feb 12. PMID: 39939431.

22: Spyridonidis A, Labopin M, Savani BP, Kulagin A, Blaise D, Broers AEC, Sica S, Raiola AM, Vydra J, Choi G, Rovira M, Kwon M, Sanz J, Itälä-Remes M, von dem Borne P, Esquirol A, Koc Y, Brissot E, Nagler A, Mohty M, Ciceri F. The impact of individual comorbidities in transplant recipients receiving post-transplant cyclophosphamide. *Bone Marrow Transplant.* 2025 Apr;60(4):499-506. doi: 10.1038/s41409-025-02514-4. Epub 2025 Feb 5. PMID: 39910175.

23: Moraru S, Malard F, Banet A, Capes A, Bonnin A, Stocker N, Sestili S, Belhocine R, Suner L, Ikhlef S, Van de Wyngaert Z, Brissot E, Mohty M, Ricard L. T-cell-based immunotherapies for human immunodeficiency virus patient with relapsed/refractory multiple myeloma: A success story from our clinic. *Br J Haematol.* 2025 Mar;206(3):988-991. doi: 10.1111/bjh.20002. Epub 2025 Jan 29. PMID: 39887985.

24: Fadel K, Siblany L, Mohty R, Stocker N, Suner L, Brissot E, Banet A, Sestili S, Duléry R, Van de Wyngaert Z, Ricard L, Belhocine R, Bonnin A, Capes A, Ledraa T, De Vassoigne F, Sokol H, Mohty M, Gaugler B, Malard F. sMAdCAM-1 is decreased after allo-HCT, along with gut microbiota dysbiosis, and is associated with hematopoietic recovery. *Hemasphere.* 2025 Jan 27;9(1):e70074. doi: 10.1002/hem3.70074. PMID: 39872963; PMCID: PMC11770326.

25: Stocker N, Alsuliman T, Corre E, Ricard L, Kaoui F, Coppo P, Brissot E, Dulery R, Banet A, Van de Wyngaert Z, Legrand O, Bonnin A, Mohty M, Malard F, Marjanovic Z. Incidence and impact of other malignancies after immunochemotherapy by fludarabine, cyclophosphamide, and rituximab as frontline treatment for chronic lymphocytic leukemia: A single-center retrospective study. *Clin Hematol Int.* 2025 Jan 3;7(1):1-9. doi: 10.46989/001c.127828. PMID: 39764201; PMCID: PMC11700516.

26: Duque-Afonso J, Finke J, Ngoya M, Galimard JE, Schetelig J, Eder M, Rösler W, Bug G, Neubauer A, Edinger M, Wulf GG, Jindra P, Einsele H, Stelljes M, Selleslag D, Wagner-Drouet EM, Bunjes D, Spyridonidis A, Brissot E, Nagler A, Ciceri F, Mohty M. Comparison of fludarabine/melphalan (FM140) with fludarabine/melphalan/BCNU (FBM110) in patients with relapsed/refractory AML undergoing allogeneic hematopoietic cell transplantation - a registry study on behalf of the EBMT Acute Leukemia Working Party. *Bone Marrow Transplant.* 2025 Mar;60(3):373-379. doi: 10.1038/s41409-024-02499-6. Epub 2024 Dec 19. PMID: 39702670; PMCID: PMC11893469.

27: Capes A, Morin A, Banet A, Suner L, Ricard L, Corre E, Brissot E, Stocker N, Marjanovic Z, Sarkozy C, Mohty M, Malard F. Severe cytopenia after chimeric antigen receptor-T cell driven by large granular lymphocytes and responsive to steroids. *Br J Haematol.* 2025 Jan;206(1):180-185. doi: 10.1111/bjh.19822. Epub 2024 Oct 19. PMID: 39425562; PMCID: PMC11739765.

28: Chevallier P, Leguay T, Delord M, Salek C, Kim R, Huguet F, Hicheri Y, Wartiovaara-Kautto U, Raffoux E, Cluzeau T, Balsat M, Roth-Guepin G, Tavernier E, Lepretre S, Bilger K, Berguignat H, Berceau A, Alexis M, Doubek M, Brissot E,

Hunault-Berger M, Lebon D, Turlure P, Chantepie S, Belhabri A, Wickenhauser S, Bastie JN, Cacheux V, Himberlin C, Banos A, Gardin C, Bonnet S, Plantier I, Pica GM, Escoffre-Barbe M, Boissel N, Dombret H, Clappier E, Rousselot P; Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL) and the European Working Group for Adult Acute Lymphoblastic Leukemia (EWALL); European Working Group for Adult Acute Lymphoblastic Leukemia (EWALL). Inotuzumab Ozogamicin and Low-Intensity Chemotherapy in Older Patients With Newly Diagnosed CD22⁺</sup> Philadelphia Chromosome-Negative B-Cell Precursor Acute Lymphoblastic Leukemia. *J Clin Oncol*. 2024 Dec 20;42(36):4327-4341. doi: 10.1200/JCO.24.00490. Epub 2024 Oct 17. PMID: 39418626.

29: Puisset F, Raffoux E, Ades L, Huynh T, Itzykson R, Bouscary D, Aguinana L, Rabian F, Sebert M, Vekhoff A, Brissot E, Mohty M, Bonnain A, Genthon A, Zerbit J, Willems L, Decroq J, Contejean A, Lengline E, Mourah S, Goldwirt L. Exposure toxicity of venetoclax in acute myeloid leukemia patients in the real-life setting: impact of high exposure on delayed neutropenia. *Haematologica*. 2025 Jul 1;110(7):1649-1653. doi: 10.3324/haematol.2024.286062. Epub 2024 Oct 17. PMID: 39415682; PMCID: PMC12208149.

30: Larue M, Labopin M, Brissot E, Alaskar AS, Aljurf M, Arat M, Baron F, Bazarbachi A, Ciceri F, Corbacioglu S, Dignan FL, Kenyon M, Malard F, Nagler A, Pagliuca A, Ruggeri A, Yakoub-Agha I, Ye Y, Duarte RF, Ruutu T, Carreras E, Peric Z, Mohty M. An international survey to better understand the current incidence, severity, and management of VOD/SOS. *Bone Marrow Transplant*. 2025 Jan;60(1):28-31. doi: 10.1038/s41409-024-02434-9. Epub 2024 Oct 7. PMID: 39375526.

31: Alsuliman T, Rojas RMM, Moukalled N, Brissot E, Quarez-Blaise L, Marjanovic Z, Blaise D, Murphy D, Logue M, Savani BN, Mohty M. Sexual health and emotional wellbeing of patients with haematological malignancies: general review. *Lancet Haematol*. 2024 Oct;11(10):e770-e779. doi: 10.1016/S2352-3026(24)00208-4. Epub 2024 Sep 20. PMID: 39312924.

32: Rabian F, Beauvais D, Marchand T, Fürst S, Huynh A, Brissot E, Maury S, Gabellier L, Chevallier P, Loschi M, Nguyen S, Balsat M, Lafon I, Fayard A, Camus V, Simand C, Moya N, Castilla-Llorente C, Joris M, Berceau A, Thiebaut-Bertrand A, Lhéritier V, Gehlkopf E, Roth-Guépin G, Leguay T, Boissel N. Efficacy and tolerance of brexucabtagene autoleucel in adults with R/R B-ALL: a GRAALL study from the DESCAR-T registry. *Blood Adv*. 2024 Nov 12;8(21):5493-5496. doi: 10.1182/bloodadvances.2024013962. PMID: 39207868; PMCID: PMC11532742.

33: Beurier P, Dalleval CA, Brissot E, Cholet C, Santin A, Lionnet F, Fain O, Mekinian A; on behalf MINHEMON. Mise en rémission par allogreffe de cellules souches hématopoïétiques d'une péri artérite noueuse associée à un syndrome myélodysplasique réfractaire à l'azacytidine [Allogeneic haematopoietic stem cell transplantation induced remission of periarteritis nodosa associated with azacytidine-refractory myelodysplastic syndrome]. *Rev Med Interne*. 2024 Aug;45(8):512-515. French. doi: 10.1016/j.revmed.2024.06.002. Epub 2024 Aug 6. PMID: 39112315.

34: Giebel S, Labopin M, Peric Z, Passweg J, Blaise D, Salmenniemi U, Beauvais D, Reményi P, Chevallier P, Mielke S, Gedde-Dahl T, Cornelissen JJ, Balsat M, Bug G, Bazarbachi A, Brissot E, Nagler A, Ciceri F, Mohty M. Impact of the Type of Tyrosine Kinase Inhibitor (imatinib or dasatinib) Used Before allo-HCT on Outcome of Patients with Philadelphia-Positive Acute Lymphoblastic Leukemia. A Study on Behalf of the Acute Leukemia Working Party of the EBMT. *Transplant Cell Ther*. 2025 Jan;31(1):14.e1-14.e10. doi: 10.1016/j.jctc.2024.07.016. Epub 2024 Jul 26. PMID: 39069077.

35: Piemontese S, Labopin M, Choi G, Broers AEC, Peccatori J, Meijer E, Van Gorkom G, Rovira M, Pascual Cascon MJ, Sica S, Vydra J, Kulagin A, Spyridonidis A, Nagler A, Bazarbachi A, Savani B, Brissot E, Sanz J, Mohty M, Ciceri F. Older MRD vs. younger MRD in patients older than 50 years with AML in remission using post-transplant cyclophosphamide. *Leukemia*. 2024 Sep;38(9):2016-2022. doi: 10.1038/s41375-024-02359-8. Epub 2024 Jul 24. PMID: 39048722.

36: Kim R, Chalandon Y, Rousselot P, Cayuela JM, Hugué F, Balsat M, Passet M, Chevallier P, Hicheri Y, Raffoux E, Leguay T, Chantepie S, Maury S, Hayette S, Solly F, Braun T, De Prijck B, Cacheux V, Salanoubat C, Farnault L, Guibaud I, Lamarque M, Gastaud L, Lemasle E, Brissot E, Tavernier E, Bilger K, Villate A, Soulier J, Graux C, Lhéritier V, Dombret H, Boissel N, Clappier E. Significance of Measurable Residual Disease in Adult Philadelphia Chromosome-Positive ALL: A GRAAPH-2014 Study. *J Clin Oncol*. 2024 Sep 10;42(26):3140-3150. doi: 10.1200/JCO.24.00108. Epub 2024 Jul 19. PMID: 39028928.

37: Bug G, Labopin M, Kulagin A, Blaise D, Raiola AM, Vydra J, Sica S, Kwon M, López-Corral L, Bramanti S, von dem Borne P, Itälä-Remes M, Martino M, Koc Y, Brissot E, Giebel S, Nagler A, Ciceri F, Mohty M. Tacrolimus versus cyclosporine a combined with post-transplantation cyclophosphamide for AML in first complete remission: a study from the acute leukemia working party (EBMT). *Bone Marrow Transplant*. 2024 Oct;59(10):1394-1401. doi: 10.1038/s41409-024-02331-1. Epub 2024 Jul 3. PMID: 38961258; PMCID: PMC11452337.

38: El Cheikh J, Ngoya M, Galimard JE, Reményi P, Kulagin A, Aljurf M, Mousavi A, Wu D, Ozcelik T, Salmenniemi U, Castilla-Llorente C, Socie G, Helbig G, Schroeder T, Sakellari I, Rambaldi A, Burt R, Busca A, Balsat M, Stelljes M, Brissot E, Giebel S, Peric Z, Nagler A, Bazarbachi A, Ciceri F, Mohty M. Prognostic factors impacting post-transplant outcomes in adult T-cell acute lymphoblastic leukemia: a registry-based study by the EBMT acute leukemia working party. *Bone Marrow Transplant*. 2024 Sep;59(9):1239-1246. doi: 10.1038/s41409-024-02300-8. Epub 2024 Jun 4. PMID: 38834689.

39: Siblany L, Stocker N, Ricard L, Brissot E, Duléry R, Banet A, Sestili S, Belhocine R, Van de Wyngaert Z, Bonnain A, Capes A, Ledraa T, Beurier P, Fadel K, Mohty M, Gaugler B, Malard F. Unconventional T Cells Influence Clinical Outcome After Allogeneic Hematopoietic Cell Transplantation. *J Clin Immunol*. 2024 Jun 1;44(6):139. doi: 10.1007/s10875-024-01741-6. PMID: 38822857.

40: Paviglianiti A, Maia T, Gozlan JM, Brissot E, Malard F, Banet A, Van de Wyngaert Z, Ledraa T, Belhocine R, Sestili S, Capes A, Stocker N, Bonnain A,

Vekhoff A, Legrand O, Mohty M, Duléry R. Human herpesvirus type 6 reactivation after haploidentical hematopoietic cell transplantation with post-transplant cyclophosphamide and antithymocyte globulin: risk factors and clinical impact. *Clin Hematol Int.* 2024 Feb 2;6(1):26-38. doi: 10.46989/001c.92525. PMID: 38817703; PMCID: PMC11087003.

41: Ye Y, Labopin M, Chen J, Wu D, Gedde-Dahl T Sr, Blaise D, Socie G, Forcade E, Salmenniemi U, Maury S, Versluis J, Bazarbachi A, Nagler A, Brissot E, Li L, Luo Y, Shi J, Ciceri F, Huang H, Mohty M, Gorin NC. Lower relapse incidence with HAPLO versus MSD or MUD HCTs for AML patients with KMT2A rearrangement: a study from the Global Committee and the ALWP of the EBMT. *Blood Cancer J.* 2024 May 27;14(1):85. doi: 10.1038/s41408-024-01072-0. PMID: 38802349; PMCID: PMC11130289.

42: Devillier R, Galimard JE, Blaise D, Raiola AM, Bramanti S, Grillo G, Pastano R, de Latour RP, Busca A, López-Corral L, Rodríguez AB, Schmid C, Forcade E, Vydra J, Solano C, Bug G, Neubauer A, Charbonnier A, Brissot E, Nagler A, Ciceri F, Mohty M. Peripheral blood stem cell versus bone marrow graft for patients ≥ 60 years undergoing reduced intensity conditioning haploidentical transplantation for acute myeloid leukemia in complete remission: An analysis of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. *Am J Hematol.* 2024 Jul;99(7):1250-1256. doi: 10.1002/ajh.27343. Epub 2024 May 23. PMID: 38778766.

43: Bazarbachi AH, Labopin M, Raiola AM, Blaise D, Arcese W, Santarone S, Koc Y, Bramanti S, Kulagin A, Kwon M, Sica S, Sanz J, Brissot E, Nagler A, Ciceri F, Mohty M. Posttransplant cyclophosphamide versus anti-thymocyte globulin versus combination for graft-versus-host disease prevention in haploidentical transplantation for adult acute myeloid leukemia: A report from the European Society for Blood and Marrow Transplantation Acute Leukemia Working Party. *Cancer.* 2024 Sep 15;130(18):3123-3136. doi: 10.1002/cncr.35365. Epub 2024 May 17. PMID: 38758817.

44: Ye Y, Labopin M, Gérard S, Yakoub-Agha I, Blau IW, Aljurf M, Forcade E, Gedde-Dahl T, Burns D, Vydra J, Halaheh K, Hamladji RM, Bazarbachi A, Nagler A, Brissot E, Li L, Luo Y, Zhao Y, Ciceri F, Huang H, Mohty M, Gorin NC. Lower relapse incidence with haploidentical versus matched sibling or unrelated donor hematopoietic cell transplantation for core-binding factor AML patients in CR2: A study from the Global Committee and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. *Am J Hematol.* 2024 Jul;99(7):1290-1299. doi: 10.1002/ajh.27342. Epub 2024 Apr 24. PMID: 38654658.

45: Alsuliman T, Aubrun C, Bay JO, Beguin Y, Bigenwald C, Brissot E, Chalandon Y, Chevallier P, Pagliuca S, Magro L, Srour M. Toxicités hématologiques après CAR-T cells, recommandations de la Société francophone de greffe de moelle et de thérapie cellulaire (SFGM-TC) [Hematological toxicities post-CAR-T cells: Recommendations of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)]. *Bull Cancer.* 2025 Jan;112(15):S103-S110. French. doi: 10.1016/j.bulcan.2024.02.013. Epub 2024 Apr 16. PMID: 38631984.

46: Nagler A, Labopin M, Swoboda R, Schroeder T, Hamladji RM, Griskevicius L, Salmenniemi U, Rambaldi A, Mielke S, Kulagin A, Passweg J, Luft T, Gedde-Dahl T, Forcade E, Helbig G, Stelljes M, Castilla-Llorente C, Spyridonidis A, Brissot E, Ciceri F, Mohty M. Post-transplant cyclophosphamide, calcineurin inhibitor, and mycophenolate mofetil compared to anti-thymocyte globulin, calcineurin inhibitor, and methotrexate combinations as graft-versus-host disease prophylaxis post allogeneic stem cell transplantation from sibling and unrelated donors in patients with acute myeloid leukemia: a study on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. *Bone Marrow Transplant.* 2024 Jul;59(7):1012-1021. doi: 10.1038/s41409-024-02284-5. Epub 2024 Apr 13. PMID: 38615143.

47: Accorsi Buttini E, Doran C, Malagola M, Radici V, Galli M, Rubini V, Leoni A, Farina M, Polverelli N, Re F, Bernardi S, Mohty M, Russo D, Brissot E. Donor Lymphocyte Infusion in the Treatment of Post-Transplant Relapse of Acute Myeloid Leukemias and Myelodysplastic Syndromes Significantly Improves Overall Survival: A French-Italian Experience of 134 Patients. *Cancers (Basel).* 2024 Mar 26;16(7):1278. doi: 10.3390/cancers16071278. PMID: 38610955; PMCID: PMC11011045.

48: Loke J, Labopin M, Craddock C, Socie G, Gedde-Dahl T, Blaise D, Forcade E, Salmenniemi U, Huynh A, Versluis J, Yakoub-Agha I, Labussière-Wallet H, Maertens J, Passweg J, Bulabois CE, Gabellier L, Mielke S, Castilla-Llorente C, Deconinck E, Brissot E, Nagler A, Ciceri F, Mohty M. Prognostic impact of number of induction courses to attain complete remission in patients with acute myeloid leukemia transplanted with either a matched sibling or human leucocyte antigen 10/10 or 9/10 unrelated donor: An Acute Leukemia Working Party European Society for Blood and Marrow Transplantation study. *Cancer.* 2024 Aug 1;130(15):2642-2651. doi: 10.1002/cncr.35308. Epub 2024 Apr 6. PMID: 38581695.

49: Bazarbachi A, Labopin M, Moukalled N, Kröger N, Rautenberg C, Schetelig J, Finke J, Blau IW, Blaise D, Stelljes M, Eder M, Platzbecker U, Dreger P, Bethge W, Tischer J, Burns D, Sengeloev H, Brissot E, Giebel S, Nagler A, Ciceri F, Mohty M. Improvements in Posttransplant Outcomes Over Two Decades in Older Patients with Acute Myeloid Leukemia in the EBMT ALWP Study. *Clin Cancer Res.* 2024 May 1;30(9):1778-1787. doi: 10.1158/1078-0432.CCR-23-3673. PMID: 38514469.

50: Sanz J, Labopin M, Blaise D, Raiola AM, Busca A, Vydra J, Tischer J, Chevallier P, Bramanti S, Fanin R, Socie G, Forcade E, Kröger N, Koc Y, Itälä-Remes M, Zecca M, Nagler A, Brissot E, Spyridonidis A, Bazarbachi A, Giebel S, Piemontese S, Mohty M, Ciceri F. Haploidentical stem cell donor choice for patients with acute myeloid leukemia: a study from the ALWP of the EBMT. *Blood Adv.* 2024 May 28;8(10):2332-2341. doi: 10.1182/bloodadvances.2023012133. PMID: 38429091; PMCID: PMC11127221.

51: Brissot E, Labopin M, Labussière H, Fossard G, Chevallier P, Guillaume T, Yakoub-Agha I, Srour M, Bulabois CE, Huynh A, Chantepie S, Menard AL, Rubio MT, Ceballos P, Dulery R, Furst S, Malard F, Blaise D, Mohty M. Post-transplant cyclophosphamide versus anti-thymocyte globulin after reduced intensity peripheral blood allogeneic cell transplantation in recipients of matched sibling or 10/10 HLA matched unrelated donors: final analysis of a randomized,

open-label, multicenter, phase 2 trial. *Blood Cancer J.* 2024 Feb 19;14(1):31. doi: 10.1038/s41408-024-00990-3. PMID: 38374026; PMCID: PMC10876658.

52: Sadowska-Klasa A, Zaucha JM, Labopin M, Bourhis JH, Blaise D, Yakoub-Agha I, Salmenniemi U, Passweg J, Fegueux N, Schroeder T, Giebel S, Brissot E, Ciceri F, Mohty M. Allogeneic hematopoietic cell transplantation is equally effective in secondary acute lymphoblastic leukemia (ALL) compared to de-novo ALL—a report from the EBMT registry. *Bone Marrow Transplant.* 2024 Mar;59(3):387-394. doi: 10.1038/s41409-023-02192-0. Epub 2024 Jan 9. PMID: 38195982.

53: Spyridonidis A, Labopin M, Gedde-Dahl T, Ganser A, Stelljes M, Craddock C, Wagner-Drouet EM, Versluis J, Schroeder T, Blau IW, Wulf GG, Dreger P, Olesen G, Sengeloev H, Kröger N, Potter V, Forcade E, Passweg J, de Latour RP, Maertens J, Wilson KMO, Bourhis JH, Finke J, Brissot E, Bazarbachi A, Giebel S, Savani BP, Nagler A, Ciceri F, Mohty M. Validation of the transplant conditioning intensity (TCI) index for allogeneic hematopoietic cell transplantation. *Bone Marrow Transplant.* 2024 Feb;59(2):217-223. doi: 10.1038/s41409-023-02139-5. Epub 2023 Nov 17. PMID: 37978322; PMCID: PMC10849946.

54: Nagler A, Labopin M, Blaise D, Raiola AM, Corral LL, Bramanti S, Sica S, Kwon M, Koc Y, Pavlu J, Kulagin A, Busca A, Rodríguez AB, Reményi P, Schmid C, Brissot E, Sanz J, Bazarbachi A, Giebel S, Ciceri F, Mohty M. Correction: Non-T-depleted haploidentical transplantation with post-transplant cyclophosphamide in patients with secondary versus de novo AML in first complete remission: a study from the ALWP/EBMT. *J Hematol Oncol.* 2023 Sep 29;16(1):106. doi: 10.1186/s13045-023-01501-w. Erratum for: *J Hematol Oncol.* 2023 May 29;16(1):58. doi: 10.1186/s13045-023-01450-4. PMID: 37775766; PMCID: PMC10543832.

55: Malard F, Battipaglia G, Gaugler B, Siblany L, van de Wyngaert Z, Bonnin A, Duléry R, Banet A, Stocker N, Ricard L, Brissot E, Mohty M. Microbiota dysbiosis after high-dose melphalan and autologous hematopoietic cell transplantation in multiple myeloma. *Bone Marrow Transplant.* 2023 Nov;58(11):1275-1278. doi: 10.1038/s41409-023-02078-1. Epub 2023 Aug 22. PMID: 37608072.

56: Duléry R, Malard F, Brissot E, Banet A, Sestili S, Belhocine R, Calabro M, Van de Wyngaert Z, Bonnin A, Ledraa T, Legrand O, Labopin M, Capderou E, Cohen A, Ederhy S, Mohty M. Reduced post-transplant cyclophosphamide dose with antithymocyte globulin in peripheral blood stem cell haploidentical transplantation. *Bone Marrow Transplant.* 2023 Nov;58(11):1215-1222. doi: 10.1038/s41409-023-02085-2. Epub 2023 Aug 18. PMID: 37596473.

57: Notarantonio AB, D'aveni-Piney M, Pagliuca S, Ashraf Y, Galimard JE, Xhaard A, Marçais A, Suarez F, Brissot E, Feugier P, Urien S, Bouazza N, Jacquelin S, Meatchi T, Bruneval P, Frémeaux-Bacchi V, Peffault De Latour R, Hermine O, Durey-Dragon MA, Rubio MT. Systemic complement activation influences outcomes after allogeneic hematopoietic cell transplantation: A prospective French multicenter trial. *Am J Hematol.* 2023 Oct;98(10):1559-1570. doi: 10.1002/ajh.27030. Epub 2023 Jul 22. PMID: 37483161.

58: Nagler A, Labopin M, Blaise D, Raiola AM, Corral LL, Bramanti S, Sica S, Kwon M, Koc Y, Pavlu J, Kulagin A, Busca A, Rodríguez AB, Reményi P, Schmid C, Brissot E, Sanz J, Bazarbachi A, Giebel S, Ciceri F, Mohty M. Non-T-depleted haploidentical transplantation with post-transplant cyclophosphamide in patients with secondary versus de novo AML in first complete remission: a study from the ALWP/EBMT. *J Hematol Oncol.* 2023 May 29;16(1):58. doi: 10.1186/s13045-023-01450-4. Erratum in: *J Hematol Oncol.* 2023 Sep 29;16(1):106. doi: 10.1186/s13045-023-01501-w. PMID: 37248463; PMCID: PMC10226209.

59: Hirschbühl K, Labopin M, Polge E, Blaise D, Bourhis JH, Socié G, Forcade E, Yakoub-Agha I, Labussière-Wallet H, Bethge W, Chevallier P, Bonnet S, Stelljes M, Spyridonidis A, Peric Z, Brissot E, Savani B, Giebel S, Schmid C, Ciceri F, Nagler A, Mohty M. Total body irradiation versus busulfan based intermediate intensity conditioning for stem cell transplantation in ALL patients >45 years—a registry-based study by the Acute Leukemia Working Party of the EBMT. *Bone Marrow Transplant.* 2023 Aug;58(8):874-880. doi: 10.1038/s41409-023-01966-w. Epub 2023 May 5. PMID: 37147469; PMCID: PMC10400409.

60: Bigot J, Leroy J, Chouaki T, Cholley L, Bigé N, Tabone MD, Brissot E, Thorez S, Maizel J, Dupont H, Sendid B, Hennequin C, Guitard J. β -D-Glucan Assay in the Cerebrospinal Fluid for the Diagnosis of Non-cryptococcal Fungal Infection of the Central Nervous System: A Retrospective Multicentric Analysis and a Comprehensive Review of the Literature. *Clin Infect Dis.* 2023 Sep 11;77(5):711-720. doi: 10.1093/cid/ciad274. PMID: 37132362.

61: Mohty M, Malard F, Alaskar AS, Aljurf M, Arat M, Bader P, Baron F, Bazarbachi A, Blaise D, Brissot E, Ciceri F, Corbacioglu S, Dalle JH, Dignan F, Huynh A, Kenyon M, Nagler A, Pagliuca A, Peric Z, Richardson PG, Ruggeri A, Ruutu T, Yakoub-Agha I, Duarte RF, Carreras E. Diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a refined classification from the European society for blood and marrow transplantation (EBMT). *Bone Marrow Transplant.* 2023 Jul;58(7):749-754. doi: 10.1038/s41409-023-01992-8. Epub 2023 Apr 24. PMID: 37095231.

62: Duléry R, Brissot E, Mohty M. Combining post-transplant cyclophosphamide with antithymocyte globulin for graft-versus-host disease prophylaxis in hematological malignancies. *Blood Rev.* 2023 Nov;62:101080. doi: 10.1016/j.blre.2023.101080. Epub 2023 Apr 11. PMID: 37085459.

63: Abou Dalle I, Labopin M, Kröger N, Schroeder T, Finke J, Stelljes M, Neubauer A, Blaise D, Yakoub-Agha I, Salmenniemi U, Forcade E, Itälä-Remes M, Dreger P, Bug G, Passweg J, Heuser M, Choi G, Brissot E, Giebel S, Nagler A, Ciceri F, Bazarbachi A, Mohty M. Impact of disease burden on clinical outcomes of AML patients receiving allogeneic hematopoietic cell transplantation: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. *Bone Marrow Transplant.* 2023 Jul;58(7):784-790. doi: 10.1038/s41409-023-01961-1. Epub 2023 Apr 11. PMID: 37041215.

64: Muhsen IN, Galeano S, Niederwieser D, Koh MBC, Ljungman P, Machado CM, Kharfan-Dabaja MA, de la Camara R, Kodera Y, Szer J, Rasheed W, Cesaro S, Hashmi SK, Seber A, Atsuta Y, Saleh MFM, Srivastava A, Styczynski J, Alrajhi A,

Almaghrabi R, Abid MB, Chemaly RF, Gergis U, Brissot E, El Fakih R, Riches M, Mikulska M, Worel N, Weisdorf D, Greinix H, Cordonnier C, Aljurf M. Endemic or regionally limited parasitic and fungal infections in haematopoietic stem-cell transplantation recipients: a Worldwide Network for Blood and Marrow Transplantation (WBMT) Review. *Lancet Haematol*. 2023 Apr;10(4):e295-e305. doi: 10.1016/S2352-3026(23)00031-5. PMID: 36990624.

65: Muhsen IN, Galeano S, Niederwieser D, Koh MBC, Ljungman P, Machado CM, Kharfan-Dabaja MA, de la Camara R, Koderia Y, Szer J, Rasheed W, Cesaro S, Hashmi SK, Seber A, Atsuta Y, Saleh MFM, Srivastava A, Styczynski J, Alrajhi A, Almaghrabi R, Abid MB, Chemaly RF, Gergis U, Brissot E, El Fakih R, Riches M, Mikulska M, Worel N, Weisdorf D, Greinix H, Cordonnier C, Aljurf M. Endemic or regionally limited bacterial and viral infections in haematopoietic stem-cell transplantation recipients: a Worldwide Network for Blood and Marrow Transplantation (WBMT) Review. *Lancet Haematol*. 2023 Apr;10(4):e284-e294. doi: 10.1016/S2352-3026(23)00032-7. PMID: 36990623.

66: Nagler A, Labopin M, Dholaria B, Blaise D, Bondarenko S, Vydra J, Choi G, Rovira M, Reményi P, Meijer E, Bulabois CE, Díez-Martin JL, Yakoub-Agha I, Brissot E, Spyridonidis A, Sanz J, Patel A, Arat M, Bazarbachi A, Bug G, Savani BN, Giebel S, Ciceri F, Mohty M. Impact of measurable residual disease on outcomes of unrelated donor haematopoietic cell transplantation with post-transplant cyclophosphamide in AML in first complete remission. *Br J Haematol*. 2023 Jun;201(6):1169-1178. doi: 10.1111/bjh.18765. Epub 2023 Mar 22. PMID: 36949658.

67: Hermans SJF, Versluis J, Labopin M, Giebel S, van Norden Y, Moiseev I, Blaise D, Díez Martín JL, Meijer E, Rovira M, Choi G, Raiola AM, Koc Y, Reményi P, Vydra J, Kröger N, Sica S, Martino M, van Gorkom G, Chevallier P, Busca A, Herrera Arroyo C, Brissot E, Peric Z, Nagler A, Shouval R, Ciceri F, Cornelissen JJ, Mohty M. Prediction of Nonrelapse Mortality in Patients With Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia Receiving Allogeneic Stem Cell Transplantation With Posttransplantation Cyclophosphamide-based Graft Versus Host Disease Prophylaxis. *Hemasphere*. 2023 Feb 21;7(3):e846. doi: 10.1097/HS9.0000000000000846. PMID: 36844179; PMCID: PMC9946411.

68: Giebel S, Labopin M, Socié G, Aljurf M, Salmenniemi U, Labussière-Wallet H, Srour M, Kröger N, Zahrani MA, Lioure B, Reményi P, Arat M, Bourhis JH, Helbig G, Tbakhi A, Forcade E, Huynh A, Brissot E, Spirydonidis A, Savani BN, Peric Z, Nagler A, Mohty M. Fludarabine or cyclophosphamide in combination with total body irradiation as myeloablative conditioning prior to allogeneic hematopoietic cell transplantation for acute lymphoblastic leukemia: an analysis by the Acute Leukemia Working Party of the EBMT. *Bone Marrow Transplant*. 2023 May;58(5):506-513. doi: 10.1038/s41409-023-01917-5. Epub 2023 Feb 1. PMID: 36725978.

69: Mohty R, El Hamed R, Brissot E, Bazarbachi A, Mohty M. New drugs before, during, and after hematopoietic stem cell transplantation for patients with acute myeloid leukemia. *Haematologica*. 2023 Feb 1;108(2):321-341. doi: 10.3324/haematol.2022.280798. PMID: 36722403; PMCID: PMC9890036.

70: Duléry R, Goudet C, Mannina D, Bianchessi A, Granata A, Harbi S, Maisano V, Chabannon C, Malard F, Brissot E, Sestili S, Banet A, Van de Wyngaert Z, Belhocine R, Ederhy S, Castagna L, Bramanti S, Blaise D, Mohty M, Fürst S, Devillier R. Reduced post-transplant cyclophosphamide doses in haploidentical hematopoietic cell transplantation for elderly patients with hematological malignancies. *Bone Marrow Transplant*. 2023 Apr;58(4):386-392. doi: 10.1038/s41409-022-01908-y. Epub 2022 Dec 30. PMID: 36585459.

71: Otiniano A, van de Wyngaert Z, Brissot E, Duléry R, Gozlan J, Daguanel A, Abi Aad Y, Ricard L, Stocker N, Banet A, Bonnin A, Alsuliman T, Marjanovic Z, Schnuriger A, Coppo P, Legrand O, Lacombe K, Mohty M, Malard F. Tixagevimab/cilgavimab for Omicron SARS-CoV-2 infection in patients with haematologic diseases. *Bone Marrow Transplant*. 2023 Mar;58(3):340-342. doi: 10.1038/s41409-022-01894-1. Epub 2022 Dec 8. PMID: 36481838; PMCID: PMC9734768.

72: Wiecek M, Labopin M, Castagna L, Brissot E, Socié G, Raiola AM, Angelucci E, Rodríguez AB, Yakoub-Agha I, Aljurf M, Crawley C, Mear JB, Musso M, Fanin R, Avenoso D, Turlure P, Tecchio C, Sanz J, Ciceri F, Nagler A, Mohty M. Post-transplant cyclophosphamide in acute leukemia patients receiving more than 5/10 HLA-mismatched allogeneic hematopoietic cell transplantation from related donors: A study on behalf of the ALWP of the EBMT. *Am J Hematol*. 2023 Feb;98(2):E41-E44. doi: 10.1002/ajh.26782. Epub 2022 Nov 30. PMID: 36398703.

73: Chauvet P, Paviglianiti A, Labopin M, Labussière H, Boissel N, Robin M, Maillard N, Ouachée-Chardin M, Forcade E, Poiré X, Chantepie S, Huynh A, Bulabois CE, Leclerc M, Maury S, Chevallier P, Cluzeau T, Mear JB, Cornillon J, Bilger K, Simand C, Beguin Y, Rubio MT, Yakoub-Agha I, Brissot E. Combining blinatumomab and donor lymphocyte infusion in B-ALL patients relapsing after allogeneic hematopoietic cell transplantation: a study of the SFGM-TC. *Bone Marrow Transplant*. 2023 Jan;58(1):72-79. doi: 10.1038/s41409-022-01846-9. Epub 2022 Oct 19. PMID: 36261707.

74: Nagler A, Labopin M, Swoboda R, Pioltelli P, Arat M, Yakoub-Agha I, Kulagin A, Maria Raiola A, Ozdogu H, Risitano A, Nur Ozkurt Z, Sanz J, Brissot E, Zina P, Giebel S, Ciceri F, Mohty M. Haploidentical Versus Matched Sibling Donor Hematopoietic Stem Cell Transplantation for Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia: A Study From the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. *Hemasphere*. 2022 Oct 13;6(11):e790. doi: 10.1097/HS9.0000000000000790. PMID: 36258924; PMCID: PMC9575736.

75: Kharfan-Dabaja MA, Labopin M, Bazarbachi A, Salmenniemi U, Mielke S, Chevallier P, Thérèse Rubio M, Balsat M, Pioltelli P, Menard AL, Socié G, Huynh A, Schaap N, Bermúdez Rodríguez A, Cornelissen JJ, Yakoub-Agha I, Aljurf M, Giebel S, Brissot E, Peric Z, Nagler A, Mohty M. CNS Involvement at Initial Diagnosis and Risk of Relapse After Allogeneic HCT for Acute Lymphoblastic Leukemia in First Complete Remission. *Hemasphere*. 2022 Oct 12;6(11):e788. doi: 10.1097/HS9.0000000000000788. PMID: 36258923; PMCID: PMC9561382.

- 76: Benjamin R, Jain N, Maus MV, Boissel N, Graham C, Jozwik A, Yallop D, Konopleva M, Frigault MJ, Teshima T, Kato K, Boucaud F, Balandraud S, Gianella-Borradori A, Binlich F, Marchiq I, Dupouy S, Almena-Carrasco M, Pannaux M, Fouliard S, Brissot E, Mohty M; CALM Study Group. UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM): a phase 1, dose-escalation trial. *Lancet Haematol.* 2022 Nov;9(11):e833-e843. doi: 10.1016/S2352-3026(22)00245-9. Epub 2022 Oct 10. PMID: 36228643; PMCID: PMC11575699.
- 77: Banet A, Bazarbachi A, Labopin M, Stocker N, Duléry R, Malard F, Van de Wyngaert Z, Genthon A, Memoli M, Legrand O, Bonnin A, Ledraa T, Belhocine R, Sestili S, El-Cheikh J, Mohty M, Brissot E. Thiotepa, busulfan and fludarabine conditioning-regimen is a promising approach for older adult patients with acute lymphoblastic leukemia treated with allogeneic stem cell transplantation. *Bone Marrow Transplant.* 2023 Jan;58(1):61-67. doi: 10.1038/s41409-022-01841-0. Epub 2022 Oct 12. PMID: 36224494.
- 78: Nagler A, Labopin M, Arat M, Reményi P, Koc Y, Blaise D, Angelucci E, Vydra J, Kulagin A, Socié G, Rovira M, Sica S, Aljurf M, Gülbas Z, Kröger N, Brissot E, Peric Z, Giebel S, Ciceri F, Mohty M. Posttransplant cyclophosphamide-based anti-graft-vs-host disease prophylaxis in patients with acute lymphoblastic leukemia treated in complete remission with allogeneic hematopoietic cell transplantation from human leukocyte antigen-mismatched unrelated donors versus haploidentical donors: A study on behalf of the ALWP of the EBMT. *Cancer.* 2022 Nov 15;128(22):3959-3968. doi: 10.1002/cncr.34452. Epub 2022 Sep 15. PMID: 36110063.
- 79: Spyridonidis A, Labopin M, Brissot E, Moiseev I, Cornelissen J, Choi G, Ciceri F, Vydra J, Reményi P, Rovira M, Meijer E, Labussière-Wallet H, Blaise D, van Gorkom G, Kröger N, Koc Y, Giebel S, Bazarbachi A, Savani B, Nagler A, Mohty M. Should anti-thymocyte globulin be added in post-transplant cyclophosphamide based matched unrelated donor peripheral blood stem cell transplantation for acute myeloid leukemia? A study on behalf of the Acute Leukemia Working Party of the EBMT. *Bone Marrow Transplant.* 2022 Dec;57(12):1774-1780. doi: 10.1038/s41409-022-01816-1. Epub 2022 Sep 7. PMID: 36071114.
- 80: Mohty R, Al Hamed R, Bazarbachi A, Brissot E, Nagler A, Zeidan A, Mohty M. Treatment of myelodysplastic syndromes in the era of precision medicine and immunomodulatory drugs: a focus on higher-risk disease. *J Hematol Oncol.* 2022 Aug 31;15(1):124. doi: 10.1186/s13045-022-01346-9. PMID: 36045390; PMCID: PMC9429775.
- 81: Nagler A, Labopin M, Dholaria B, Ciceri F, Fraccaroli A, Blaise D, Fanin R, Bruno B, Forcade E, Vydra J, Chevallier P, Bulabois CE, Jindra P, Bornhäuser M, Canaan J, Sanz J, Savani BN, Spyridonidis A, Giebel S, Brissot E, Bazarbachi A, Esteve J, Mohty M. Impact of Cytogenetic Risk on Outcomes of Non-T-Cell-Depleted Haploidentical Hematopoietic Cell Transplantation in Patients with Relapsed or Refractory Acute Myeloid Leukemia. *Transplant Cell Ther.* 2022 Nov;28(11):773.e1-773.e8. doi: 10.1016/j.jctc.2022.08.018. Epub 2022 Aug 27. PMID: 36031079.
- 82: Rialland F, Grain A, Labopin M, Michel G, Gandemer V, Paillard C, Pochon C, Clement L, Brissot E, Jubert C, Sirvent A, Rohrlisch PS, Plantaz D, Dalle JH, Mohty M. Reduced-toxicity myeloablative conditioning regimen using fludarabine and full doses of intravenous busulfan in pediatric patients not eligible for standard myeloablative conditioning regimens: Results of a multicenter prospective phase 2 trial. *Bone Marrow Transplant.* 2022 Nov;57(11):1698-1703. doi: 10.1038/s41409-022-01769-5. Epub 2022 Aug 26. PMID: 36028757.
- 83: Radici V, Brissot E, Chartier S, Guitard J, Fabiani B, Memoli M, Banet A, Heuberger L, Lapusan S, Atallah S, Legrand O, Genthon A. Invasive Fungal Rhinosinusitis Due to Co-infection with Mucormycosis and *Exserohilum rostratum* in a Patient with Acute Lymphoblastic Leukemia. *Clin Hematol Int.* 2022 Jun 13;4(1-2):60-64. doi: 10.1007/s44228-022-00009-3. PMID: 35950207; PMCID: PMC9358779.
- 84: Kreidieh F, Abou Dalle I, Moukalled N, El-Cheikh J, Brissot E, Mohty M, Bazarbachi A. Relapse after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia: an overview of prevention and treatment. *Int J Hematol.* 2022 Sep;116(3):330-340. doi: 10.1007/s12185-022-03416-7. Epub 2022 Jul 16. PMID: 35841458.
- 85: Stocker N, Baltes V, Bellaiche S, Brouillard F, Belmoufid N, Rousseau C, Bonnin A, Van de Wyngaert Z, Ricard L, Banet A, Malard F, Duléry R, Mohty M, Brissot E. Photobiomodulation: a promising innovative approach for preventing oral mucositis in patients undergoing hematopoietic stem cell transplantation. *Support Care Cancer.* 2022 Oct;30(10):8211-8216. doi: 10.1007/s00520-022-07280-3. Epub 2022 Jul 9. PMID: 35810217.
- 86: Devillier R, Galimard JE, Labopin M, Blaise D, Raiola AM, Pavlu J, Castagna L, Socié G, Chalandon Y, Martino M, Stölzel F, Bug G, Bruno B, Vrhovac R, Charbonnier A, Olivieri A, Bay JO, Arroyo H, Yakoub-Agha I, Avenoso D, Neubauer A, Nguyen S, Forcade E, Brissot E, Savani B, Nagler A, Mohty M. Reduced intensity versus non-myeloablative conditioning regimen for haploidentical transplantation and post-transplantation cyclophosphamide in complete remission acute myeloid leukemia: a study from the ALWP of the EBMT. *Bone Marrow Transplant.* 2022 Sep;57(9):1421-1427. doi: 10.1038/s41409-022-01674-x. Epub 2022 Jun 25. PMID: 35752739.
- 87: Kohn M, Alsuliman T, Lamure S, Cheminant M, Delage J, Merle De Boever C, Tudesq JJ, Marjanovic Z, Van de Wyngaert Z, Malard F, Brissot E, Rigaudeau S, Marque-Juillet S, Therby A, Cartron G, Rousselot P, Hermine O, Duléry R, Besson C. Characteristics of SARS-CoV-2 infection in lymphoma/chronic lymphocytic leukemia patients during the Omicron outbreak. *Leuk Lymphoma.* 2022 Nov;63(11):2686-2690. doi: 10.1080/10428194.2022.2086249. Epub 2022 Jun 18. PMID: 35719107.
- 88: Genthon A, Dragoi D, Memoli M, Hirsch P, Favale F, Suner L, Chaquin M, Boncoeur P, Marjanovic Z, Bonnin A, Sestili S, Duléry R, Malard F, Brissot E,

- Banet A, van de Wyngaert Z, Vekhoff A, Delhommeau F, Mohty M, Legrand O. Isocitrate dehydrogenase inhibitors as a bridge to allogeneic stem cell transplant in relapsed or refractory acute myeloid leukaemia. *Br J Haematol*. 2022 Aug;198(4):780-784. doi: 10.1111/bjh.18290. Epub 2022 May 26. PMID: 35615877.
- 89: Loke J, Labopin M, Craddock C, Cornelissen JJ, Labussière-Wallet H, Wagner-Drouet EM, Van Gorkom G, Schaap NPM, Kröger NM, Veelken JH, Rovira M, Menard AL, Bug G, Bazarbachi A, Giebel S, Brissot E, Nagler A, Esteve J, Mohty M. Additional cytogenetic features determine outcome in patients allografted for TP53 mutant acute myeloid leukemia. *Cancer*. 2022 Aug 1;128(15):2922-2931. doi: 10.1002/cncr.34268. Epub 2022 May 25. PMID: 35612815; PMCID: PMC9545190.
- 90: Grain A, Riolland-Battisti F, Chevallier P, Blin N, Dalle JH, Michel G, Dhédin N, Peffault de Latour R, Pochon C, Yakoub-Agha I, Bertrand Y, Sirvent A, Jubert C, Forcade E, Berceanu A, Gandemer V, Schneider P, Bay JO, Röhrlich PS, Brissot E, Paillard C, Plantaz D, Nguyen Quoc S, Gonzales F, Maillard N, Planche L, Baruchel A. Hematopoietic stem cell transplantation for acute lymphoblastic leukemia: why do adolescents and young adults outcomes differ from those of children? A retrospective study on behalf of the Francophone Society of Stem Cell Transplantation and Cellular Therapy (SFGM-TC). *J Cancer Res Clin Oncol*. 2023 Apr;149(4):1473-1483. doi: 10.1007/s00432-022-04021-1. Epub 2022 May 4. PMID: 35507103; PMCID: PMC11797360.
- 91: Memoli M, Genthon A, Favale F, Lapusan S, Johnson N, Adaeva R, Deswarte C, Battipaglia G, Malard F, Duléry R, Brissot E, Banet A, Van de Wyngaert Z, Mohty M, Delhommeau F, Legrand O, Hirsch P. Prognostic impact of early minimal residual disease combined with complete molecular evaluation in acute myeloid leukemia with mutated *NPM1*: a single center study. *Leuk Lymphoma*. 2022 Sep;63(9):2171-2179. doi: 10.1080/10428194.2022.2064987. Epub 2022 Apr 22. PMID: 35459427.
- 92: Rodríguez-Arbolí E, Labopin M, Eder M, Brecht A, Blau IW, Huynh A, Forcade E, Tischer J, Bethge W, Bondarenko S, Verbeek M, Bulabois CE, Einsele H, Stölzel F, Savani B, Spyridonidis A, Bazarbachi A, Giebel S, Brissot E, Schmid C, Nagler A, Mohty M. Augmented FLAMSA-Bu versus FluBu2 reduced-intensity conditioning in patients with active relapsed/refractory acute myeloid leukemia: an EBMT analysis. *Bone Marrow Transplant*. 2022 Jun;57(6):934-941. doi: 10.1038/s41409-022-01611-y. Epub 2022 Apr 7. PMID: 35393528.
- 93: Cabannes-Hamy A, Brissot E, Leguay T, Huguet F, Chevallier P, Hunault M, Escoffre-Barbe M, Cluzeau T, Balsat M, Nguyen S, Pasquier F, Alexis M, Lheritier V, Pastoret C, Delabesse E, Clappier E, Dombret H, Boissel N. High tumor burden before blinatumomab has a negative impact on the outcome of adult patients with B-cell precursor acute lymphoblastic leukemia. A real-world study by the GRAALL. *Haematologica*. 2022 Sep 1;107(9):2072-2080. doi: 10.3324/haematol.2021.280078. PMID: 35263986; PMCID: PMC9425331.
- 94: Borde C, Quignon F, Amiel C, Gozlan J, Marechal V, Brissot E. Methyl-qPCR: a new method to investigate Epstein-Barr virus infection in post-transplant lymphoproliferative diseases. *Clin Epigenetics*. 2022 Mar 4;14(1):33. doi: 10.1186/s13148-022-01255-1. PMID: 35246247; PMCID: PMC8895795.
- 95: Radici V, Stocker N, Dulery R, Brissot E, Bannet A, van de Wyngaert Z, Sestili S, Belhocine R, Bonin A, Ledraa T, Mohty M, Malard F. Low incidence of hyperacute graft-versus-host disease (GVHD) with effective GVHD prophylaxis based on anti-thymocyte globulin. *Br J Haematol*. 2022 Jun;197(5):630-633. doi: 10.1111/bjh.18099. Epub 2022 Mar 4. PMID: 35245388.
- 96: Bigot J, Godmer A, Prudenté L, Angebault C, Brissot E, Bige N, Voiriot G, Leger PL, Petit-Hoang C, Atallah S, Gouache E, Senghor Y, Valot S, Hennequin C, Guitard J. Diagnosis of mucormycosis using an intercalating dye-based quantitative PCR. *Med Mycol*. 2022 Mar 12;60(4):myac015. doi: 10.1093/mmy/myac015. PMID: 35188208.
- 97: Beauvais D, Robin C, Thiebaut A, Alain S, Coiteux V, Ducastelle-Lepretre S, Marçais A, Ceballos P, Xhaard A, Redjoul R, Nguyen S, Brissot E, Joris M, Turlure P, Rubio MT, Chevallier P, Bénard N, Liautard C, Yakoub-Agha I. Effective Letermovir Prophylaxis of CMV infection post allogeneic hematopoietic cell transplantation: Results from the French temporary authorization of use compassionate program. *J Clin Virol*. 2022 Mar;148:105106. doi: 10.1016/j.jcv.2022.105106. Epub 2022 Feb 15. PMID: 35182958.
- 98: Nagler A, Labopin M, Huang XJ, Blaise D, Arcese W, Araujo MC, Socié G, Forcade E, Ciceri F, Canaani J, Giebel S, Brissot E, Caballer JS, Bazarbachi A, Yakoub-Agha I, Mohty M. Non-T depleted haploidentical stem cell transplantation in AML patients achieving first complete remission after one versus two induction courses: a study from the ALWP/EBMT. *Bone Marrow Transplant*. 2022 Apr;57(4):572-578. doi: 10.1038/s41409-021-01537-x. Epub 2022 Feb 1. PMID: 35105964.
- 99: Bazarbachi A, Labopin M, Aljurf M, Niittyvuopio R, Balsat M, Blaise D, Yakoub-Agha I, Grassi A, Reinhardt HC, Lenhoff S, Jindra P, Passweg J, Abou Dalle I, Stadler M, Lioure B, Ceballos P, Brissot E, Giebel S, Nagler A, Schmid C, Mohty M. 20-Year Steady Increase in Survival of Adult Patients with Relapsed Philadelphia-Positive Acute Lymphoblastic Leukemia Post Allogeneic Hematopoietic Cell Transplantation. *Clin Cancer Res*. 2022 Mar 1;28(5):1004-1012. doi: 10.1158/1078-0432.CCR-21-2675. PMID: 35022319.
- 100: Paccoud O, Alain S, Gozlan J, Jarboui S, Boutolleau D, Hantz S, Battipaglia G, Paviglianiti A, Duléry R, Malard F, Médiavilla C, Sestili S, Gaugler B, Meynard JL, Pacanowski J, Mohty M, Brissot E. Immune restoration therapy for multidrug-resistant CMV disease in an allogeneic stem cell transplant recipient. *Curr Res Transl Med*. 2022 May;70(2):103329. doi: 10.1016/j.retram.2021.103329. Epub 2022 Jan 10. PMID: 35021130.
- 101: Alsuliman T, Stocker N, de Wyngaert ZV, Ikhlef S, Ellouz C, Corre E, Banet A, Ricard L, Dulery R, Meynard JL, Malard F, Stankoff B, Farge-Bancel D, Brissot E, Mohty M, Marjanovic Z. COVID-19 in the context of autologous hematopoietic stem cell transplantation for a patient with autoimmune disease. *Curr Res Transl*

Med. 2022 May;70(2):103332. doi: 10.1016/j.retram.2021.103332. Epub 2021 Dec 24. PMID: 34979485; PMCID: PMC8702398.

102: Nagler A, Labopin M, Dholaria B, Wu D, Choi G, Aljurf M, Ciceri F, Gedde-Dahl T, Meijer E, Niittyvuopio R, Bondarenko S, Bourhis JH, Cornelissen JJ, Socié G, Koc Y, Canaani J, Savani B, Bug G, Spyridonidis A, Giebel S, Brissot E, Bazarbachi A, Esteve J, Mohty M. Graft-versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide versus Cyclosporine A and Methotrexate in Matched Sibling Donor Transplantation. *Transplant Cell Ther.* 2022 Feb;28(2):86.e1-86.e8. doi: 10.1016/j.jtct.2021.11.013. Epub 2021 Nov 29. PMID: 34856420.

103: Paviglianiti A, Sestili S, Bianchessi A, Memoli M, Dulery R, Banet A, Van De Wyngaert Z, Belhocine R, Ledraa T, Malard F, Mohty M, Brissot E. Stable pulmonary function after haploidentical stem cell transplantation with post-transplant cyclophosphamide: a single center experience. *Leuk Lymphoma.* 2022 Feb;63(2):443-449. doi: 10.1080/10428194.2021.1984460. Epub 2021 Sep 29. PMID: 34587856.

104: Pochon C, Detrait M, Dalle JH, Michel G, Dhédin N, Chalandon Y, Brissot E, Forcade E, Sirvent A, Izzadifar-Légrand F, Michallet M, Renard C, Yakoub-Agha I, Gonzales F, Bay JO, Kanold J, Cornillon J, Bulabois CE, Angoso M, Nguyen S, Balza M, Chevallier P, Rialland F, Bazarbachi A, Beguin Y, Huynh A, Ménard AL, Schneider P, Neven B, Paillard C, Raus N, Albuissou E, Remen T, Rubio MT. Improved outcome in children compared to adolescents and young adults after allogeneic hematopoietic stem cell transplant for acute myeloid leukemia: a retrospective study from the Francophone Society of Bone Marrow Transplantation and Cell Therapy (SFGM-TC). *J Cancer Res Clin Oncol.* 2022 Aug;148(8):2083-2097. doi: 10.1007/s00432-021-03761-w. Epub 2021 Sep 4. PMID: 34480598; PMCID: PMC9293841.

105: Gournay V, Dumas G, Lavillegrand JR, Hariri G, Urbina T, Baudel JL, Ait-Oufella H, Maury E, Brissot E, Légrand O, Malard F, Mohty M, Guidet B, Duléry R, Bigé N. Outcome of allogeneic hematopoietic stem cell transplant recipients admitted to the intensive care unit with a focus on haploidentical graft and sequential conditioning regimen: results of a retrospective study. *Ann Hematol.* 2021 Nov;100(11):2787-2797. doi: 10.1007/s00277-021-04640-7. Epub 2021 Sep 3. PMID: 34476574.

106: Duléry R, Mohty R, Labopin M, Sestili S, Malard F, Brissot E, Battipaglia G, Médiavilla C, Banet A, Van de Wyngaert Z, Paviglianiti A, Belhocine R, Isnard F, Lapusan S, Adaeva R, Vekhoff A, Ledraa T, Légrand O, Cohen A, Bonnin A, Ederhy S, Mohty M. Early Cardiac Toxicity Associated With Post-Transplant Cyclophosphamide in Allogeneic Stem Cell Transplantation. *JACC CardioOncol.* 2021 Jun 15;3(2):250-259. doi: 10.1016/j.jacc.2021.02.011. PMID: 34396331; PMCID: PMC8352028.

107: Malard F, Gaugler B, Gozlan J, Bouquet L, Fofana D, Siblany L, Eshagh D, Adotevi O, Laheurte C, Ricard L, Dulery R, Stocker N, van de Wyngaert Z, Genthon A, Banet A, Memoli M, Ikhlef S, Sestili S, Vekhof A, Brissot E, Marjanovic Z, Chantran Y, Cuervo N, Ballot E, Morand-Joubert L, Mohty M. Weak immunogenicity of SARS-CoV-2 vaccine in patients with hematologic malignancies. *Blood Cancer J.* 2021 Aug 10;11(8):142. doi: 10.1038/s41408-021-00534-z. PMID: 34376633; PMCID: PMC8353615.

108: Malard F, Lavelle A, Battipaglia G, Gaugler B, Dulery R, Brissot E, Médiavilla C, Jegou S, Rolhion N, Ledraa T, Mohty R, Sokol H, Mohty M. Impact of gut fungal and bacterial communities on the outcome of allogeneic hematopoietic cell transplantation. *Mucosal Immunol.* 2021 Sep;14(5):1127-1132. doi: 10.1038/s41385-021-00429-z. Epub 2021 Jul 19. PMID: 34282272.

109: Pegliasco J, Hirsch P, Marzac C, Isnard F, Meniane JC, Deswarte C, Pellet P, Lemaitre C, Leroy G, Rabadan Moraes G, Guermouche H, Schmaltz-Panneau B, Pasquier F, Colas C, Benusiglio PR, Bera O, Bourhis JH, Brissot E, Caron O, Chraïbi S, Cony-Makhoul P, Delaunay-Darivon C, Lapusan S, de Fontbrune FS, Fuseau P, Najman A, Vainchenker W, Delhommeau F, Micol JB, Plo I, Bellanné-Chantelot C. Germline ATG2B/GSKIP-containing 14q32 duplication predisposes to early clonal hematopoiesis leading to myeloid neoplasms. *Leukemia.* 2022 Jan;36(1):126-137. doi: 10.1038/s41375-021-01319-w. Epub 2021 Jun 25. PMID: 34172895.

110: Salvator H, Tcherakian C, Maillard N, Milin S, Bergeron A, Bodeelle L, Meignin V, Nguyen S, Souchet L, Guenounou S, Evrard SM, Rubio MT, Robin M, Sestili S, Brissot E, Fajac A, Catherinot E, Givel C, Chabrol A, Goyard C, Longchamp E, Chabi-Charvillat ML, Bernaudin JF, Couderc LJ. Pulmonary Alveolar Proteinosis After Allogeneic Hematopoietic Stem-Cell Transplantation in Adults: A French Société Francophone de Greffe de Moelle et Thérapie Cellulaire Survey. *Chest.* 2021 Nov;160(5):1783-1788. doi: 10.1016/j.chest.2021.05.056. Epub 2021 Jun 5. PMID: 34102143.

111: Jolivet S, Couturier J, Vuillemin X, Gouot C, Nesa D, Adam M, Brissot E, Mohty M, Bonnin RA, Dortet L, Barbut F. Outbreak of OXA-48-producing Enterobacteriales in a haematological ward associated with an uncommon environmental reservoir, France, 2016 to 2019. *Euro Surveill.* 2021 May;26(21):2000118. doi: 10.2807/1560-7917.ES.2021.26.21.2000118. PMID: 34047273; PMCID: PMC8161731.

112: Kharfan-Dabaja MA, Labopin M, Bazarbachi A, Ciceri F, Finke J, Bruno B, Bornhäuser M, Gedde-Dahl T, Labussière-Wallet H, Niittyvuopio R, Valerius T, Angelucci E, Brecht A, Caballero D, Kuball J, Potter V, Schmid C, Tischer J, Zuckerman T, Benedetti F, Blaise D, Diez-Martin JL, Sanz J, Ruggeri A, Brissot E, Savani BN, Giebel S, Nagler A, Mohty M. Comparing outcomes of a second allogeneic hematopoietic cell transplant using HLA-matched unrelated versus T-cell replete haploidentical donors in relapsed acute lymphoblastic leukemia: a study of the Acute Leukemia Working Party of EBMT. *Bone Marrow Transplant.* 2021 Sep;56(9):2194-2202. doi: 10.1038/s41409-021-01317-7. Epub 2021 Apr 30. PMID: 33931757.

113: Savani M, Dulery R, Bazarbachi AH, Mohty R, Brissot E, Malard F, Bazarbachi A, Nagler A, Mohty M. Allogeneic haematopoietic cell transplantation for

- myelofibrosis: a real-life perspective. *Br J Haematol.* 2021 Nov;195(4):495-506. doi: 10.1111/bjh.17469. Epub 2021 Apr 21. PMID: 33881169.
- 114: Brissot E, Troadec MB, Loréal O, Brissot P. Iron and platelets: A subtle, under-recognized relationship. *Am J Hematol.* 2021 Aug 1;96(8):1008-1016. doi: 10.1002/ajh.26189. Epub 2021 May 14. PMID: 33844865.
- 115: Mohty R, Savani M, Brissot E, Mohty M. Nutritional Supplements and Complementary/Alternative Medications in Patients With Hematologic Diseases and Hematopoietic Stem Cell Transplantation. *Transplant Cell Ther.* 2021 Jun;27(6):467-473. doi: 10.1016/j.jtct.2021.03.011. Epub 2021 Mar 14. PMID: 33839088.
- 116: Kharfan-Dabaja MA, Labopin M, Brissot E, Kroger N, Finke J, Ciceri F, Deconinck E, Blaise D, Chevallier P, Gramatzki M, Ganser A, Stelljes M, Edinger M, Savani B, Ruggeri A, Sanz J, Nagler A, Mohty M. Second allogeneic haematopoietic cell transplantation using HLA-matched unrelated versus T-cell replete haploidentical donor and survival in relapsed acute myeloid leukaemia. *Br J Haematol.* 2021 May;193(3):592-601. doi: 10.1111/bjh.17426. Epub 2021 Apr 10. PMID: 33838047.
- 117: Nagler A, Labopin M, Houhou M, Aljurf M, Mousavi A, Hamladji RM, Al Zahrani M, Bondarenko S, Arat M, Angelucci E, Koc Y, Gülbas Z, Sica S, Bourhis JH, Canaani J, Brissot E, Giebel S, Mohty M. Outcome of haploidentical versus matched sibling donors in hematopoietic stem cell transplantation for adult patients with acute lymphoblastic leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. *J Hematol Oncol.* 2021 Apr 1;14(1):53. doi: 10.1186/s13045-021-01065-7. PMID: 33794963; PMCID: PMC8017786.
- 118: Alsuliman T, Faict S, Malard F, Genthon A, Brissot E, Van de Wyngaert Z, Ikhlef S, Banet A, Lapusan S, Sestili S, Corre E, M'hammedi-Bouzina F, Schaeffer L, Legrand O, Duléry R, Mohty M, Marjanovic Z. Does Ibrutinib impact outcomes of viral infection by SARS-CoV-2 in mantle cell lymphoma patients? *Curr Res Transl Med.* 2021 Jan;69(1):103273. doi: 10.1016/j.retram.2020.103273. Epub 2020 Nov 25. PMID: 33460953; PMCID: PMC7687383.
- 119: Genthon A, Chiarabini T, Baylac P, Valin N, Urbina T, Pacanowski J, Mekinian A, Brissot E, M'Hammedi-Bouzina F, Lapusan S, Mohty M, Lacombe K, Ingiliz P. Severe COVID-19 infection in a patient with paroxysmal nocturnal hemoglobinuria on eculizumab therapy. *Leuk Lymphoma.* 2021 Jun;62(6):1502-1505. doi: 10.1080/10428194.2020.1869963. Epub 2021 Jan 8. PMID: 33416421.
- 120: Beauvais D, Drumez E, Blaise D, Peffault de Latour R, Forcade E, Ceballos P, Uyttebroeck A, Labussière H, Nguyen S, Bourhis JH, Chevallier P, Thiebaut A, Poiré X, Maury S, Deconinck E, Cluzeau T, Brissot E, Huynh A, Rubio MT, Duhamel A, Yakoub-Agha I. Scoring system for clinically significant CMV infection in seropositive recipients following allogeneic hematopoietic cell transplant: an SFGM-TC study. *Bone Marrow Transplant.* 2021 Jun;56(6):1305-1315. doi: 10.1038/s41409-020-01178-6. Epub 2020 Dec 18. PMID: 33339900.
- 121: Benjamin R, Graham C, Yallop D, Jozwik A, Mirzi-Danicar OC, Lucchini G, Pinner D, Jain N, Kantarjian H, Boissel N, Maus MV, Frigault MJ, Baruchel A, Mohty M, Gianella-Borradori A, Binlich F, Balandraud S, Vitry F, Thomas E, Philippe A, Fouliard S, Dupouy S, Marchiq I, Almena-Carrasco M, Ferry N, Arnould S, Konto C, Veys P, Qasim W; UCART19 Group. Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies. *Lancet.* 2020 Dec 12;396(10266):1885-1894. doi: 10.1016/S0140-6736(20)32334-5. PMID: 33308471; PMCID: PMC11773457.
- 122: Battipaglia G, Labopin M, Hamladji RM, Blaise D, Chevallier P, Brissot E, Gerbitz A, Socié G, Afanasyev B, Ciceri F, Meijer E, Koc Y, Cornelissen JJ, Huynh A, Ozdogu H, Maertens J, Paul F, Labussière-Wallet H, Ruggeri A, Aljurf M, Bazarbachi A, Savani B, Nagler A, Mohty M. Post-transplantation cyclophosphamide versus antithymocyte globulin in patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation from HLA-identical sibling donors: A retrospective analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. *Cancer.* 2021 Jan 15;127(2):209-218. doi: 10.1002/cncr.33255. Epub 2020 Oct 29. PMID: 33119152.
- 123: Memoli M, Paviglianiti A, Malard F, Battipaglia G, Brissot E, Médiavilla C, Bianchessi A, Banet A, Van de Wyngaert Z, Ledraa T, Belhocine R, Sestili S, Lapusan S, Hirsch P, Favale F, Boussarouque A, Bonnin A, Vekhoff A, Legrand O, Mohty M, Duléry R. Thiotepa-busulfan-fludarabine as a conditioning regimen for patients with myelofibrosis undergoing allogeneic hematopoietic transplantation: a single center experience. *Leuk Lymphoma.* 2021 Feb;62(2):419-427. doi: 10.1080/10428194.2020.1827246. Epub 2020 Oct 5. PMID: 33012207.
- 124: Stocker N, Gaugler B, Labopin M, Farge A, Ye Y, Ricard L, Brissot E, Duléry R, Sestili S, Battipaglia G, Médiavilla C, Paviglianiti A, Banet A, Van De Wyngaert Z, Ledraa T, Mohty M, Malard F. High-dose post-transplant cyclophosphamide impairs $\gamma\delta$ T-cell reconstitution after haploidentical haematopoietic stem cell transplantation using low-dose antithymocyte globulin and peripheral blood stem cell graft. *Clin Transl Immunology.* 2020 Sep 23;9(9):e1171. doi: 10.1002/cti2.1171. PMID: 33005413; PMCID: PMC7511259.
- 125: Dhédin N, Paillard C, Dalle JH, Ouachée M, Buchbinder N, Brissot E, Beguin Y, Masouridi-Levrat S, Yakoub-Agha I, Bernin E, Pondarre C. Allogreffe de cellules souches hématopoïétiques dans la drépanocytose de l'enfant et de l'adulte : indications et modalités [Allogeneic hematopoietic stem cell transplant in children and adults with sickle cell disease: Indications and modalities]. *Bull Cancer.* 2020 Sep;107(9):925-933. French. doi: 10.1016/j.bulcan.2020.06.003. Epub 2020 Sep 10. PMID: 32921398.
- 126: Brissot P, Brissot E. What's Important and New in Hemochromatosis? *Clin Hematol Int.* 2020 Aug 5;2(4):143-148. doi: 10.2991/chi.k.200726.001. PMID: 34595455; PMCID: PMC8432403.
- 127: Genthon A, Brissot E, Malard F, van de Wyngaert Z, Bonnin A, Banet A,

Marjanovic Z, Ikhlef S, Lapusan S, Sestili S, Corre E, Paviglianiti A, Adaeva R, 'Hammedi-Bouzina FM, Labopin M, Dulery R, Mohty M, Legrand O. Gemtuzumab Ozogamicin Combined With Intensive Chemotherapy in Patients With Acute Myeloid Leukemia Relapsing After Allogeneic Stem Cell Transplantation. *Clin Lymphoma Myeloma Leuk*. 2020 Dec;20(12):791-796. doi: 10.1016/j.clml.2020.07.001. Epub 2020 Jul 6. PMID: 32741743.

128: Nagler A, Baron F, Labopin M, Polge E, Esteve J, Bazarbachi A, Brissot E, Bug G, Ciceri F, Giebel S, Gilleece MH, Gorin NC, Lanza F, Peric Z, Ruggeri A, Sanz J, Savani BN, Schmid C, Shouval R, Spyridonidis A, Versluis J, Mohty M. Measurable residual disease (MRD) testing for acute leukemia in EBMT transplant centers: a survey on behalf of the ALWP of the EBMT. *Bone Marrow Transplant*. 2021 Jan;56(1):218-224. doi: 10.1038/s41409-020-01005-y. Epub 2020 Jul 28. PMID: 32724200.

129: Ye Y, Ricard L, Siblany L, Stocker N, De Vassoigne F, Brissot E, Lamarthée B, Mekinian A, Mohty M, Gaugler B, Malard F. Arsenic trioxide induces regulatory functions of plasmacytoid dendritic cells through interferon- α inhibition. *Acta Pharm Sin B*. 2020 Jun;10(6):1061-1072. doi: 10.1016/j.apsb.2020.01.016. Epub 2020 Jan 31. PMID: 32642412; PMCID: PMC7332672.

130: Brissot E, Labopin M, Moiseev I, Cornelissen JJ, Meijer E, Van Gorkom G, Rovira M, Ciceri F, Griskevicius L, Blaise D, Forcade E, Mistrik M, Mielke S, Bulabois CE, Niittyvuopio R, Deconinck E, Ruggeri A, Sanz J, Spyridonidis A, Savani B, Giebel S, Nagler A, Mohty M. Post-transplant cyclophosphamide versus antithymocyte globulin in patients with acute myeloid leukemia in first complete remission undergoing allogeneic stem cell transplantation from 10/10 HLA-matched unrelated donors. *J Hematol Oncol*. 2020 Jul 3;13(1):87. doi: 10.1186/s13045-020-00923-0. PMID: 32620146; PMCID: PMC7333262.

131: Couturier J, Ginevra C, Nesa D, Adam M, Gouot C, Descours G, Campèse C, Battipaglia G, Brissot E, Beraud L, Ranc AG, Jarraud S, Barbut F. Transmission of Legionnaires' Disease through Toilet Flushing. *Emerg Infect Dis*. 2020 Jul;26(7):1526-1528. doi: 10.3201/eid2607.190941. PMID: 32568063; PMCID: PMC7323554.

132: Brissot E, Labopin M, Baron F, Bazarbachi A, Bug G, Ciceri F, Esteve J, Giebel S, Gilleece MH, Gorin NC, Lanza F, Peric Z, Ruggeri A, Sanz J, Savani BN, Schmid C, Shouval R, Spyridonidis A, Versluis J, Nagler A, Mohty M. Management of patients with acute leukemia during the COVID-19 outbreak: practical guidelines from the acute leukemia working party of the European Society for Blood and Marrow Transplantation. *Bone Marrow Transplant*. 2021 Mar;56(3):532-535. doi: 10.1038/s41409-020-0970-x. Epub 2020 Jun 11. PMID: 32528122; PMCID: PMC7289070.

133: Sestili S, Eder S, Belhocine R, Dulery R, Battipaglia G, Brissot E, Mediavilla C, Banet A, van de Wyngaert Z, Paviglianiti A, Ledraa T, Bonin A, Mohty M, Malard F. Extracorporeal photopheresis as first-line strategy in the treatment of acute graft-versus-host disease after hematopoietic stem cell transplantation: A single-center experience. *Cytotherapy*. 2020 Aug;22(8):445-449. doi: 10.1016/j.jcyt.2020.03.003. Epub 2020 May 18. PMID: 32434750.

134: Malard F, Genthon A, Brissot E, van de Wyngaert Z, Marjanovic Z, Ikhlef S, Banet A, Lapusan S, Sestili S, Corre E, Paviglianiti A, Adaeva R, M 'Hammedi-Bouzina F, Labopin M, Legrand O, Dulery R, Mohty M. COVID-19 outcomes in patients with hematologic disease. *Bone Marrow Transplant*. 2020 Nov;55(11):2180-2184. doi: 10.1038/s41409-020-0931-4. Epub 2020 May 6. PMID: 32376969; PMCID: PMC7201203.

135: Mohty M, Dulery R, Gauthier J, Malard F, Brissot E, Aljurf M, Bazarbachi A, Chabanon C, Kharfan-Dabaja MA, Savani BN, Huang H, Kenderian SS, Perales MA, Yakoub-Agha I, Nagler A. CAR T-cell therapy for the management of refractory/relapsed high-grade B-cell lymphoma: a practical overview. *Bone Marrow Transplant*. 2020 Aug;55(8):1525-1532. doi: 10.1038/s41409-020-0892-7. Epub 2020 Apr 18. PMID: 32305998.

136: Bazarbachi A, Bug G, Baron F, Brissot E, Ciceri F, Dalle IA, Döhner H, Esteve J, Floisand Y, Giebel S, Gilleece M, Gorin NC, Jabbour E, Aljurf M, Kantarjian H, Kharfan-Dabaja M, Labopin M, Lanza F, Malard F, Peric Z, Prebet T, Ravandi F, Ruggeri A, Sanz J, Schmid C, Shouval R, Spyridonidis A, Versluis J, Vey N, Savani BN, Nagler A, Mohty M. Clinical practice recommendation on hematopoietic stem cell transplantation for acute myeloid leukemia patients with FLT3-internal tandem duplication: a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. *Haematologica*. 2020 Jun;105(6):1507-1516. doi: 10.3324/haematol.2019.243410. Epub 2020 Apr 2. PMID: 32241850; PMCID: PMC7271578.

137: Marini C, Brissot E, Bazarbachi A, Duléry R, Sestili S, Battipaglia G, Médiavilla C, Paviglianiti A, Belhocine R, Isnard F, Lapusan S, Adaeva R, Bannet A, van de Wiegert Z, Vekhoff A, Ledraa T, Legrand O, Labopin M, Bonnin A, Ruggeri A, Malard F, Mohty M. Tolerability and Efficacy of Treatment With Azacytidine as Prophylactic or Preemptive Therapy for Myeloid Neoplasms After Allogeneic Stem Cell Transplantation. *Clin Lymphoma Myeloma Leuk*. 2020 Jun;20(6):377-382. doi: 10.1016/j.clml.2019.10.011. Epub 2019 Oct 23. PMID: 32234295.

138: Brissot E, Labopin M, Russo D, Martin S, Schmid C, Glass B, Ram R, Ozkurt ZN, Passweg J, Veelken JH, Bunjes D, Apperley J, Giebel S, Mohty M, Nagler A. Alternative donors provide comparable results to matched unrelated donors in patients with acute lymphoblastic leukemia undergoing allogeneic stem cell transplantation in second complete remission: a report from the EBMT Acute Leukemia Working Party. *Bone Marrow Transplant*. 2020 Sep;55(9):1763-1772. doi: 10.1038/s41409-020-0849-x. Epub 2020 Mar 17. PMID: 32203261.

139: Spyridonidis A, Labopin M, Savani BN, Niittyvuopio R, Blaise D, Craddock C, Socié G, Platzbecker U, Beelen D, Milpied N, Cornelissen JJ, Ganser A, Huynh A, Griskevicius L, Giebel S, Aljurf M, Brissot E, Malard F, Esteve J, Peric Z, Baron F, Ruggeri A, Schmid C, Gilleece M, Gorin NC, Lanza F, Shouval R, Versluis

J, Bug G, Fløisand Y, Ciceri F, Sanz J, Bazarbachi A, Nagler A, Mohty M. Correction: Redefining and measuring transplant conditioning intensity in current era: a study in acute myeloid leukemia patients. *Bone Marrow Transplant.* 2020 Jun;55(6):1213. doi: 10.1038/s41409-020-0835-3. Erratum for: *Bone Marrow Transplant.* 2020 Jun;55(6):1114-1125. doi: 10.1038/s41409-020-0803-y. PMID: 32144364.

140: Bôle-Richard E, Fredon M, Bichlé S, Anna F, Certoux JM, Renosi F, Tsé F, Molimard C, Valmary-Degano S, Jenvrin A, Warda W, Pallandre JR, Bonnefoy F, Poussard M, Deschamps M, Petrella T, Roumier C, Macintyre E, Féger F, Brissot E, Mohty M, HoWangYin KY, Langlade-Demoyen P, Loustau M, Caumartin J, Godet Y, Binda D, Pagadoy M, Deconinck E, Daguindau E, Saas P, Ferrand C, Angelot-Delettre F, Adotévi O, Garnache-Ottou F. CD28/4-1BB CD123 CAR T cells in blastic plasmacytoid dendritic cell neoplasm. *Leukemia.* 2020 Dec;34(12):3228-3241. doi: 10.1038/s41375-020-0777-1. Epub 2020 Feb 28. PMID: 32111969.

141: Spyridonidis A, Labopin M, Savani BN, Niittyvuopio R, Blaise D, Craddock C, Socié G, Platzbecker U, Beelen D, Milpied N, Cornelissen JJ, Ganser A, Huynh A, Griskevicius L, Giebel S, Aljurf M, Brissot E, Malard F, Esteve J, Peric Z, Baron F, Ruggeri A, Schmid C, Gillece M, Gorin NC, Lanza F, Shouval R, Versluis J, Bug G, Fløisand Y, Ciceri F, Sanz J, Bazarbachi A, Nagler A, Mohty M. Redefining and measuring transplant conditioning intensity in current era: a study in acute myeloid leukemia patients. *Bone Marrow Transplant.* 2020 Jun;55(6):1114-1125. doi: 10.1038/s41409-020-0803-y. Epub 2020 Jan 29. Erratum in: *Bone Marrow Transplant.* 2020 Jun;55(6):1213. doi: 10.1038/s41409-020-0835-3. PMID: 31996792.

142: Bazarbachi A, Labopin M, Angelucci E, Gülbaz Z, Ozdogu H, Arat M, de Rosa L, Pastano R, Pioletti P, Montserrat R, Martino M, Ciceri F, Koç Y, Socié G, Blaise D, Herrera C, Chalandon Y, Bernasconi P, Marotta G, Castagna L, McDonald A, Visani G, Carluccio P, Vitek A, Simand C, Afanasyev B, Rösler W, Diez-Martin JL, Nagler A, Brissot E, Giebel S, Mohty M. Haploidentical Transplantation with Post-Transplantation Cyclophosphamide for T Cell Acute Lymphoblastic Leukemia: A Report from the European Society for Blood and Marrow Transplantation Acute Leukemia Working Party. *Biol Blood Marrow Transplant.* 2020 May;26(5):936-942. doi: 10.1016/j.bbmt.2020.01.003. Epub 2020 Jan 9. PMID: 31926364.

143: Brissot E, Bernard DG, Loréal O, Brissot P, Troadec MB. Too much iron: A masked foe for leukemias. *Blood Rev.* 2020 Jan;39:100617. doi: 10.1016/j.blre.2019.100617. Epub 2019 Aug 31. PMID: 31753415.

144: Peric Z, Mohty R, Bastos J, Brissot E, Battipaglia G, Belhocine R, Sestili S, Giannotti F, Vekhoff A, Ledraa T, Legrand O, Lapusan S, Isnard F, Labopin M, Bonnin A, Mediavilla C, Rubio MT, Ruggeri A, Duléry R, Malard F, Mohty M. Thiotepa and antithymocyte globulin-based conditioning prior to haploidentical transplantation with posttransplant cyclophosphamide in high-risk hematological malignancies. *Bone Marrow Transplant.* 2020 Apr;55(4):763-772. doi: 10.1038/s41409-019-0726-7. Epub 2019 Oct 31. PMID: 31673080.

145: Brissot E, Villate A, Alsuliman T, Beauvais D, Bonnin A, Mear JB, Souchet L, Yakoub-Agha I, Bazarbachi A. Dépistage des bactéries multirésistantes (BMR) et hautement résistantes émergentes (BHRe) aux antibiotiques en allogreffe de cellules souches hématopoïétiques : recommandations de la Société francophone de greffe de moelle et de thérapie cellulaire (SFGM-TC) [Multidrug-resistant bacteria detection in patients undergoing allogeneic hematopoietic cell transplantation: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)]. *Bull Cancer.* 2020 Jan;107(1S):S7-S11. French. doi: 10.1016/j.bulcan.2019.09.006. Epub 2019 Oct 18. PMID: 31635753.

146: Brissot E, Alsuliman T, Beauvais D, Bonnin A, Mear JB, Souchet L, Villate A, Yakoub-Agha I, Bazarbachi A. Prophylaxie antivirale pour le CMV, l'HSV/VZV et le VHB après allogreffe de cellules souches hématopoïétiques chez l'adulte : recommandations de la Société francophone de greffe de moelle et de thérapie cellulaire (SFGM-TC) [Antiviral prophylaxis for CMV, HSV/VZV and HBV in allogeneic hematopoietic cell transplantation in adult patients: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)]. *Bull Cancer.* 2020 Jan;107(1S):S1-S6. French. doi: 10.1016/j.bulcan.2019.09.002. Epub 2019 Oct 15. PMID: 31627903.

147: Stocker N, Labopin M, Boussen I, Paccoud O, Bonnin A, Malard F, Amiel C, Gozlan J, Battipaglia G, Duléry R, Giannotti F, Ruggeri A, Gaugler B, Mohty M, Brissot E. Pre-emptive rituximab treatment for Epstein-Barr virus reactivation after allogeneic hematopoietic stem cell transplantation is a worthwhile strategy in high-risk recipients: a comparative study for immune recovery and clinical outcomes. *Bone Marrow Transplant.* 2020 Mar;55(3):586-594. doi: 10.1038/s41409-019-0699-6. Epub 2019 Sep 27. PMID: 31562397.

148: Debureaux PE, Labopin M, Mamez AC, Lapusan S, Isnard F, Adavea R, Bonnin A, Hirsch P, Delhommeau F, Battipaglia G, Duléry R, Malard F, Vekhoff A, Mohty M, Legrand O, Brissot E. Fractionated gemtuzumab ozogamicin in association with high dose chemotherapy: a bridge to allogeneic stem cell transplantation in refractory and relapsed acute myeloid leukemia. *Bone Marrow Transplant.* 2020 Feb;55(2):452-460. doi: 10.1038/s41409-019-0690-2. Epub 2019 Sep 25. PMID: 31554931.

149: Mohty R, Brissot E, Battipaglia G, Ruggeri A, Duléry R, Bonnin A, Médiavilla C, Sestili S, Belhocine R, Vekhoff A, Ledraa T, Lapusan CS, Adavea R, Isnard F, Legrand O, Mohty M, Malard F. Infectious complications after post-transplantation cyclophosphamide and anti-thymocyte globulin-based haploidentical stem cell transplantation. *Br J Haematol.* 2019 Nov;187(3):e64-e68. doi: 10.1111/bjh.16189. Epub 2019 Sep 5. PMID: 31487392.

150: Paccoud O, Guitard J, Labopin M, Surgers L, Malard F, Battipaglia G, Duléry R, Hennequin C, Mohty M, Brissot E. Features of *Toxoplasma gondii* reactivation after allogeneic hematopoietic stem-cell transplantation in a high seroprevalence setting. *Bone Marrow Transplant.* 2020 Jan;55(1):93-99. doi: 10.1038/s41409-019-0641-y. Epub 2019 Aug 21. PMID: 31435031.

151: Stocker N, Duléry R, Battipaglia G, Brissot E, Médiavilla C, Sestili S,

Paviglianiti A, Ledraa T, Mohty R, Bazarbachi A, Belhocine R, Vekhoff A, Ruggeri A, Mohty M, Malard F. Impact of cyclosporine A concentration on acute graft-vs-host disease incidence after haploidentical hematopoietic cell transplantation. *Eur J Haematol*. 2019 Jul;103(1):10-17. doi: 10.1111/ejh.13233. Epub 2019 May 14. PMID: 30958904.

152: Duléry R, Bastos J, Paviglianiti A, Malard F, Brissot E, Battipaglia G, Médiavilla C, Giannotti F, Banet A, de Wyngaert ZV, Ledraa T, Belhocine R, Sestili S, Adaeva R, Lapusan S, Isnard F, Legrand O, Vekhoff A, Rubio MT, Ruggeri A, Mohty M. Thiotepa, Busulfan, and Fludarabine Conditioning Regimen in T Cell-Replete HLA-Haploidentical Hematopoietic Stem Cell Transplantation. *Biol Blood Marrow Transplant*. 2019 Jul;25(7):1407-1415. doi: 10.1016/j.bbmt.2019.02.025. Epub 2019 Mar 11. PMID: 30871978.

153: Battipaglia G, Malard F, Rubio MT, Ruggeri A, Mamez AC, Brissot E, Giannotti F, Duléry R, Joly AC, Baylatry MT, Kossmann MJ, Tankovic J, Beaugerie L, Sokol H, Mohty M. Fecal microbiota transplantation before or after allogeneic hematopoietic transplantation in patients with hematologic malignancies carrying multidrug-resistance bacteria. *Haematologica*. 2019 Aug;104(8):1682-1688. doi: 10.3324/haematol.2018.198549. Epub 2019 Feb 7. PMID: 30733264; PMCID: PMC6669143.

154: Debureaux PE, Paccoud O, Guitard J, Baujat B, Ruggeri A, Battipaglia G, Duléry R, Giannotti F, Malard F, Mohty M, Brissot E. Rhino-orbital Mucormycosis presenting as facial cellulitis in a patient with high-risk acute myeloid leukemia in relapse. *Curr Res Transl Med*. 2019 May;67(2):76-78. doi: 10.1016/j.retram.2019.01.004. Epub 2019 Jan 25. PMID: 30686650.

155: Lewalle P, Pochon C, Michallet M, Turlure P, Brissot E, Paillard C, Puyade M, Roth-Guepin G, Yakoub-Agha I, Chantepie S. Prophylaxie des infections post-allogreffe : recommandations de la Société francophone de greffe de moelle et de thérapie cellulaire (SFGM-TC) [Prophylaxis of infections post-allogeneic transplantation: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)]. *Bull Cancer*. 2019 Jan;106(1S):S23-S34. French. doi: 10.1016/j.bulcan.2018.08.017. Epub 2019 Jan 4. PMID: 30616839.

156: Buchbinder N, Wallyn F, Lhuillier E, Hicheri Y, Magro L, Farah B, Cornillon J, Duléry R, Vincent L, Brissot E, Yakoub-Agha I, Chevallier P. Complications pulmonaires post-greffe : recommandations de la Société francophone de greffe de moelle et de thérapie cellulaire (SFGM-TC) [Post-transplant pulmonary complications: Guidelines from the francophone Society of bone marrow transplantation and cellular therapy (SFGM-TC)]. *Bull Cancer*. 2019 Jan;106(1S):S10-S17. French. doi: 10.1016/j.bulcan.2018.11.006. Epub 2018 Dec 27. PMID: 30595221.

157: Mohty R, Brissot E, Battipaglia G, Ruggeri A, Sestili S, Médiavilla C, Belhocine R, Duléry R, Mohty M, Malard F. CD34⁺-selected stem cell "Boost" for poor graft function after allogeneic hematopoietic stem cell transplantation. *Curr Res Transl Med*. 2019 Aug;67(3):112-114. doi: 10.1016/j.retram.2018.12.003. Epub 2018 Dec 25. PMID: 30591374.

158: Hicheri Y, Buchbinder N, Magro L, Farah B, Zephir H, Brissot E, Yakoub-Agha I, Chevallier P. Complications neurologiques post-allogreffe de cellules souches hématopoïétiques : recommandations de la Société francophone de greffe de moelle et de thérapie cellulaire (SFGM-TC) [Post-transplant neurological complications: Guidelines from the francophone Society of bone marrow transplantation and cellular therapy (SFGM-TC)]. *Bull Cancer*. 2019 Jan;106(1S):S18-S22. French. doi: 10.1016/j.bulcan.2018.08.015. Epub 2018 Nov 2. PMID: 30392709.

159: Brissot E, Labopin M, Ehninger G, Stelljes M, Brecht A, Ganser A, Tischer J, Kröger N, Afanasyev B, Finke J, Elmaagacli A, Einsele H, Mohty M, Nagler A. Haploidentical <i>-versus</i> unrelated allogeneic stem cell transplantation for relapsed/refractory acute myeloid leukemia: a report on 1578 patients from the Acute Leukemia Working Party of the EBMT. *Haematologica*. 2019 Mar;104(3):524-532. doi: 10.3324/haematol.2017.187450. Epub 2018 Oct 25. PMID: 30361416; PMCID: PMC6395335.

160: Brissot P, Troadec MB, Loréal O, Brissot E. Pathophysiology and classification of iron overload diseases; update 2018. *Transfus Clin Biol*. 2019 Feb;26(1):80-88. doi: 10.1016/j.tracli.2018.08.006. Epub 2018 Aug 15. PMID: 30173950.

161: Brissot P, Bernard DG, Brissot E, Loréal O, Troadec MB. Rare anemias due to genetic iron metabolism defects. *Mutat Res Rev Mutat Res*. 2018 Jul-Sep;777:52-63. doi: 10.1016/j.mrrev.2018.06.003. Epub 2018 Jun 22. PMID: 30115430.

162: Lamarthée B, de Vasseigne F, Malard F, Stocker N, Boussen I, Médiavilla C, Tang R, Fava F, Garderet L, Marjanovic Z, Brissot E, Mohty M, Gaugler B. Quantitative and functional alterations of 6-sulfo LacNac dendritic cells in multiple myeloma. *Oncoimmunology*. 2018 Mar 19;7(7):e1444411. doi: 10.1080/2162402X.2018.1444411. PMID: 29900053; PMCID: PMC5993501.

163: Picod A, Bonnin A, Battipaglia G, Giannotti F, Ruggeri A, Brissot E, Malard F, Médiavilla C, Belhocine R, Vekhoff A, Gueye MS, Lapusan S, Adaeva R, Isnard F, Legrand O, Baylatry MT, Joly AC, Labopin M, Duléry R, Mohty M. Defibrotide for Sinusoidal Obstruction Syndrome/Veno-Occlusive Disease Prophylaxis in High-Risk Adult Patients: A Single-Center Experience Study. *Biol Blood Marrow Transplant*. 2018 Jul;24(7):1471-1475. doi: 10.1016/j.bbmt.2018.02.015. Epub 2018 Mar 1. PMID: 29477779.

164: Guitard J, Isnard F, Tabone MD, Antignac M, Brissot E, Senghor Y, Petit A, Leverger G, Hennequin C. Usefulness of β -D-glucan for diagnosis and follow-up of invasive candidiasis in onco-haematological patients. *J Infect*. 2018 May;76(5):483-488. doi: 10.1016/j.jinf.2018.01.011. Epub 2018 Feb 9. PMID: 29432826.

165: Duléry R, Ménard AL, Chantepie S, El-Cheikh J, François S, Delage J, Giannotti F, Ruggeri A, Brissot E, Battipaglia G, Malard F, Belhocine R, Sestili

- S, Vekhoff A, Delhommeau F, Reman O, Legrand O, Labopin M, Rubio MT, Mohty M. Sequential Conditioning with Thiotepa in T Cell- Replete Hematopoietic Stem Cell Transplantation for the Treatment of Refractory Hematologic Malignancies: Comparison with Matched Related, Haplo-Mismatched, and Unrelated Donors. *Biol Blood Marrow Transplant.* 2018 May;24(5):1013-1021. doi: 10.1016/j.bbmt.2018.01.005. Epub 2018 Jan 11. PMID: 29337223.
- 166: Brissot E, Alsuliman T, Gruson B, Hermet E, Tirefort Y, Yakoub-Agha I, Alain S. Conduite à tenir devant une réactivation EBV et un syndrome lymphoprolifératif à EBV, une réactivation ou infection à CMV et à HHV-6 après allogreffe de cellules souches hématopoïétiques : recommandations de la SFGM-TC (mises à jour) [How to manage EBV reactivation and EBV-PTLD, CMV and human herpesvirus 6 reactivation and infection after allogeneic stem cell transplantation: A report of the SFGM-TC (update)]. *Bull Cancer.* 2017 Dec;104(12S):S181-S187. French. doi: 10.1016/j.bulcan.2017.10.022. Epub 2017 Nov 21. PMID: 29169653.
- 167: Lehrer J, Brissot E, Ruggeri A, Dulery R, Vekhoff A, Battipaglia G, Giannotti F, Fernandez C, Mohty M, Antignac M. Medication adherence among allogeneic hematopoietic stem cell transplant recipients: a pilot single-center study. *Bone Marrow Transplant.* 2018 Feb;53(2):231-233. doi: 10.1038/bmt.2017.233. Epub 2017 Nov 20. PMID: 29155420.
- 168: Brissot E, Labopin M, Stelljes M, Ehninger G, Schwerdtfeger R, Finke J, Kolb HJ, Ganser A, Schäfer-Eckart K, Zander AR, Bunjes D, Mielke S, Bethge WA, Milpied N, Kalhs P, Blau IW, Kröger N, Vitek A, Gramatzki M, Holler E, Schmid C, Esteve J, Mohty M, Nagler A. Comparison of matched sibling donors versus unrelated donors in allogeneic stem cell transplantation for primary refractory acute myeloid leukemia: a study on behalf of the Acute Leukemia Working Party of the EBMT. *J Hematol Oncol.* 2017 Jun 24;10(1):130. doi: 10.1186/s13045-017-0498-8. PMID: 28646908; PMCID: PMC5483262.
- 169: Battipaglia G, Ruggeri A, Massoud R, El Cheikh J, Jestin M, Antar A, Ahmed SO, Rasheed W, Shaheen M, Belhocine R, Brissot E, Dulery R, Eder S, Giannotti F, Isnard F, Lapusan S, Rubio MT, Vekhoff A, Aljurf M, Legrand O, Mohty M, Bazarbachi A. Efficacy and feasibility of sorafenib as a maintenance agent after allogeneic hematopoietic stem cell transplantation for Fms-like tyrosine kinase 3-mutated acute myeloid leukemia. *Cancer.* 2017 Aug 1;123(15):2867-2874. doi: 10.1002/cncr.30680. Epub 2017 Apr 7. PMID: 28387928.
- 170: Polomeni A, Bompont C, Gomez A, Brissot E, Ruggeri A, Belhocine R, Mohty M. Current practices for screening, consent and care of related donors in France: Haematopoietic stem cell transplantation coordinator nurses' perceptions. *Eur J Cancer Care (Engl).* 2017 Nov;26(6). doi: 10.1111/ecc.12612. Epub 2016 Dec 6. PMID: 27922202.
- 171: Clavert A, Peric Z, Brissot E, Malard F, Guillaume T, Delaunay J, Dubrulle V, Le Gouill S, Mahe B, Gastinne T, Blin N, Harousseau JL, Moreau P, Milpied N, Mohty M, Chevallier P. Late Complications and Quality of Life after Reduced-Intensity Conditioning Allogeneic Stem Cell Transplantation. *Biol Blood Marrow Transplant.* 2017 Jan;23(1):140-146. doi: 10.1016/j.bbmt.2016.10.011. Epub 2016 Oct 14. PMID: 27751934.
- 172: Giebel S, Czyz A, Ottmann O, Baron F, Brissot E, Ciceri F, Cornelissen JJ, Esteve J, Gorin NC, Savani B, Schmid C, Mohty M, Nagler A. Use of tyrosine kinase inhibitors to prevent relapse after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A position statement of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. *Cancer.* 2016 Oct;122(19):2941-51. doi: 10.1002/cncr.30130. Epub 2016 Jun 16. PMID: 27309127.
- 173: Li Z, Rubinstein SM, Thota R, Savani M, Brissot E, Shaw BE, Majhail NS, Mohty M, Savani BN. Immune-Mediated Complications after Hematopoietic Stem Cell Transplantation. *Biol Blood Marrow Transplant.* 2016 Aug;22(8):1368-1375. doi: 10.1016/j.bbmt.2016.04.005. Epub 2016 Apr 14. PMID: 27095688.
- 174: Malard F, Labopin M, Chevallier P, Guillaume T, Duquesne A, Rialland F, Derenne S, Peterlin P, Leauté AG, Brissot E, Gregoire M, Moreau P, Saas P, Gaugler B, Mohty M. Larger number of invariant natural killer T cells in PBSC allografts correlates with improved GVHD-free and progression-free survival. *Blood.* 2016 Apr 7;127(14):1828-35. doi: 10.1182/blood-2015-12-688739. Epub 2016 Feb 22. Erratum in: *Blood.* 2018 Oct 18;132(16):1726. doi: 10.1182/blood-2018-09-873893. PMID: 26903546.
- 175: Brissot E, Rialland F, Cahu X, Strullu M, Corradini N, Thomas C, Blin N, Rialland X, Thebaud E, Chevallier P, Moreau P, Milpied N, Harousseau JL, Mechinaud F, Mohty M. Improvement of overall survival after allogeneic hematopoietic stem cell transplantation for children and adolescents: a three-decade experience of a single institution. *Bone Marrow Transplant.* 2016 Feb;51(2):267-72. doi: 10.1038/bmt.2015.250. Epub 2015 Dec 7. PMID: 26642337.
- 176: Yong AS, Brissot E, Rubinstein S, Savani BN, Mohty M. Transplant to treatment-free remission: the evolving view of 'cure' in chronic myeloid leukemia. *Expert Rev Hematol.* 2015 Dec;8(6):785-97. doi: 10.1586/17474086.2015.1087843. Epub 2015 Sep 12. PMID: 26364871.
- 177: Ruggeri A, Roth-Guepin G, Battipaglia G, Mamez AC, Malard F, Gomez A, Brissot E, Belhocine R, Vekhoff A, Lapusan S, Isnard F, Legrand O, Gozlan J, Boutolleau D, Ledraa T, Labopin M, Rubio MT, Mohty M. Incidence and risk factors for hemorrhagic cystitis in unmanipulated haploidentical transplant recipients. *Transpl Infect Dis.* 2015 Dec;17(6):822-30. doi: 10.1111/tid.12455. Epub 2015 Nov 25. PMID: 26354178.
- 178: Battipaglia G, Ruggeri A, Brissot E, Mamez AC, Malard F, Belhocine R, Vekhoff A, Giannotti F, Ledraa T, Labopin M, Rubio MT, Mohty M. Safety and feasibility of romiplostim treatment for patients with persistent thrombocytopenia after allogeneic stem cell transplantation. *Bone Marrow Transplant.* 2015 Dec;50(12):1574-7. doi: 10.1038/bmt.2015.182. Epub 2015 Aug 17. PMID: 26281029.

- 179: Brissot E, Mohty M. Which Acute Myeloid Leukemia Patients Should Be Offered Transplantation? *Semin Hematol.* 2015 Jul;52(3):223-31. doi: 10.1053/j.seminhematol.2015.03.001. Epub 2015 Mar 17. PMID: 26111470.
- 180: Peric Z, Cahu X, Malard F, Brissot E, Chevallier P, Guillaume T, Gregoire M, Gaugler B, Mohty M. Peripheral Blood Plasmacytoid Dendritic Cells at Day 100 Can Predict Outcome after Allogeneic Stem Cell Transplantation. *Biol Blood Marrow Transplant.* 2015 Aug;21(8):1431-6. doi: 10.1016/j.bbmt.2015.04.003. Epub 2015 Apr 7. PMID: 25862590.
- 181: Brissot E, Clavert A, Blin N, Roland V, Guillaume T, Dubruille V, Mahe B, Gastinne T, Le Gouill S, Gaugler B, Moreau P, Mohty M. Impact of lenalidomide on immune functions in the setting of maintenance therapy for multiple myeloma. *Leukemia.* 2015 Oct;29(10):2098-100. doi: 10.1038/leu.2015.64. Epub 2015 Mar 9. PMID: 25748683.
- 182: Brissot E, Labopin M, Beckers MM, Socié G, Rambaldi A, Volin L, Finke J, Lenhoff S, Kröger N, Ossenkoppele GJ, Craddock CF, Yakoub-Agha I, Gürman G, Russell NH, Aljurf M, Potter MN, Nagler A, Ottmann O, Cornelissen JJ, Esteve J, Mohty M. Tyrosine kinase inhibitors improve long-term outcome of allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia. *Haematologica.* 2015 Mar;100(3):392-9. doi: 10.3324/haematol.2014.116954. Epub 2014 Dec 19. PMID: 25527562; PMCID: PMC4349279.
- 183: Brissot E, Bossard C, Malard F, Braudeau C, Chevallier P, Guillaume T, Delaunay J, Josien R, Gregoire M, Gaugler B, Mohty M. Involvement of the CX3CL1 (fractalkine)/CX3CR1 pathway in the pathogenesis of acute graft-versus-host disease. *J Leukoc Biol.* 2015 Feb;97(2):227-35. doi: 10.1189/jlb.5HI0714-325R. Epub 2014 Nov 24. PMID: 25420917.
- 184: Brissot E, Cahu X, Guillaume T, Delaunay J, Ayari S, Peterlin P, Le Bourgeois A, Housseau JL, Milpied N, Bene MC, Moreau P, Mohty M, Chevallier P. Initial fluconazole prophylaxis may not be required in adults with acute leukemia or myelodysplastic/myeloproliferative disorders after reduced intensity conditioning peripheral blood stem cell allogeneic transplantation. *Ann Hematol.* 2015 Apr;94(4):663-9. doi: 10.1007/s00277-014-2259-x. Epub 2014 Nov 21. PMID: 25409914.
- 185: Peterlin P, Delaunay J, Guillaume T, Gastinne T, Mahé B, Dubruille V, Blin N, Le Bourgeois A, Brissot E, Lodé L, Le Gouill S, Moreau P, Mohty M, Chevallier P. Complete donor T cell chimerism predicts lower relapse incidence after standard double umbilical cord blood reduced-intensity conditioning regimen allogeneic transplantation in adults. *Biol Blood Marrow Transplant.* 2015 Jan;21(1):180-4. doi: 10.1016/j.bbmt.2014.08.018. Epub 2014 Aug 28. PMID: 25175796.
- 186: Brissot E, Gomez A, Aline-Fardin A, Lalande V, Lapusan S, Isnard F, Legrand O, Meynard JL, Rubio MT, Mohty M. Report of disseminated Mycobacterium haemophilum infection after double cord blood allo-SCT. *Bone Marrow Transplant.* 2014 Oct;49(10):1347-8. doi: 10.1038/bmt.2014.144. Epub 2014 Jul 14. PMID: 25029233.
- 187: Malard F, Bossard C, Brissot E, Chevallier P, Guillaume T, Delaunay J, Mosnier JF, Moreau P, Grégoire M, Gaugler B, Mohty M. Increased Th17/Treg ratio in chronic liver GVHD. *Bone Marrow Transplant.* 2014 Apr;49(4):539-44. doi: 10.1038/bmt.2013.215. Epub 2014 Jan 13. PMID: 24419519.
- 188: de Masson A, Beylot-Barry M, Bouaziz JD, Peffault de Latour R, Aubin F, Garcia S, d'Incan M, Dereure O, Dalle S, Domp Martin A, Suarez F, Battistella M, Vignon-Pennamen MD, Rivet J, Adamski H, Brice P, François S, Lissandre S, Turlure P, Wierzbicka-Hainaut E, Brissot E, Dulery R, Servais S, Ravinet A, Tabrizi R, Ingen-Housz-Oro S, Joly P, Socié G, Bagot M; French Study Group on Cutaneous Lymphomas and Société Française de Greffe de Moëlle et Thérapie Cellulaire. Allogeneic stem cell transplantation for advanced cutaneous T-cell lymphomas: a study from the French Society of Bone Marrow Transplantation and French Study Group on Cutaneous Lymphomas. *Haematologica.* 2014 Mar;99(3):527-34. doi: 10.3324/haematol.2013.098145. Epub 2013 Nov 8. PMID: 24213148; PMCID: PMC3943317.
- 189: Bodet-Milin C, Lacombe M, Malard F, Lestang E, Cahu X, Chevallier P, Guillaume T, Delaunay J, Brissot E, Moreau P, Kraeber-Bodere F, Mohty M. 18F-FDG PET/CT for the assessment of gastrointestinal GVHD: results of a pilot study. *Bone Marrow Transplant.* 2014 Jan;49(1):131-7. doi: 10.1038/bmt.2013.144. Epub 2013 Sep 30. PMID: 24076550.
- 190: Malard F, Bossard C, Brissot E, Chevallier P, Guillaume T, Delaunay J, Mosnier JF, Moreau P, Grégoire M, Gaugler B, Mohty M. Increased plasmacytoid dendritic cells and RORyt-expressing immune effectors in cutaneous acute graft-versus-host disease. *J Leukoc Biol.* 2013 Dec;94(6):1337-43. doi: 10.1189/jlb.0513295. Epub 2013 Aug 29. PMID: 23990625.
- 191: Mohty M, Brissot E, Savani BN, Gaugler B. Effects of bortezomib on the immune system: a focus on immune regulation. *Biol Blood Marrow Transplant.* 2013 Oct;19(10):1416-20. doi: 10.1016/j.bbmt.2013.05.011. Epub 2013 May 22. PMID: 23707853.
- 192: Frikeche J, Peric Z, Brissot E, Grégoire M, Gaugler B, Mohty M. Impact of HDAC inhibitors on dendritic cell functions. *Exp Hematol.* 2012 Oct;40(10):783-91. doi: 10.1016/j.exphem.2012.06.008. Epub 2012 Jun 19. PMID: 22728031.
- 193: Strullu M, Rialland F, Cahu X, Brissot E, Corradini N, Thomas C, Blin N, Rialland X, Méchinaud F, Mohty M. Allogeneic hematopoietic stem cell transplantation following reduced-intensity conditioning regimen in children: a single-center experience. *Eur J Haematol.* 2012 Jun;88(6):504-9. doi: 10.1111/j.1600-0609.2012.01776.x. Epub 2012 Mar 21. PMID: 22372430.
- 194: Brissot E, Savani BN, Mohty M. Management of high ferritin in long-term survivors after hematopoietic stem cell transplantation. *Semin Hematol.* 2012 Jan;49(1):35-42. doi: 10.1053/j.seminhematol.2011.10.003. PMID: 22221783.

- 195: Frikeche J, Simon T, Brissot E, Grégoire M, Gaugler B, Mohty M. Impact of valproic acid on dendritic cells function. *Immunobiology*. 2012 Jul;217(7):704-10. doi: 10.1016/j.imbio.2011.11.010. Epub 2011 Dec 8. PMID: 22209114.
- 196: Bardou-Jacquet E, Island ML, Jouanolle AM, Détiavaud L, Fatih N, Ropert M, Brissot E, Mosser A, Maisonneuve H, Brissot P, Loréal O. A novel N491S mutation in the human SLC11A2 gene impairs protein trafficking and in association with the G212V mutation leads to microcytic anemia and liver iron overload. *Blood Cells Mol Dis*. 2011 Dec 15;47(4):243-8. doi: 10.1016/j.bcmd.2011.07.004. Epub 2011 Aug 26. PMID: 21871825.
- 197: Frikeche J, Clavert A, Delaunay J, Brissot E, Grégoire M, Gaugler B, Mohty M. Impact of the hypomethylating agent 5-azacytidine on dendritic cells function. *Exp Hematol*. 2011 Nov;39(11):1056-63. doi: 10.1016/j.exphem.2011.08.004. Epub 2011 Aug 18. PMID: 21856273.
- 198: Malard F, Cahu X, Clavert A, Brissot E, Chevallier P, Guillaume T, Delaunay J, Ayari S, Dubruille V, Mahe B, Gastinne T, Blin N, Harousseau JL, Moreau P, Miplied N, Le Gouill S, Mohty M. Fludarabine, antithymocyte globulin, and very low-dose busulfan for reduced-intensity conditioning before allogeneic stem cell transplantation in patients with lymphoid malignancies. *Biol Blood Marrow Transplant*. 2011 Nov;17(11):1698-703. doi: 10.1016/j.bbmt.2011.04.010. Epub 2011 May 3. PMID: 21601642.
- 199: Peric Z, Cahu X, Chevallier P, Brissot E, Malard F, Guillaume T, Delaunay J, Ayari S, Dubruille V, Le Gouill S, Mahé B, Gastinne T, Blin N, Saulquin B, Harousseau JL, Moreau P, Coste-Burel M, Imbert-Marcille BM, Mohty M. Features of EBV reactivation after reduced intensity conditioning unrelated umbilical cord blood transplantation. *Bone Marrow Transplant*. 2012 Feb;47(2):251-7. doi: 10.1038/bmt.2011.64. Epub 2011 Mar 28. PMID: 21441959.
- 200: Peric Z, Cahu X, Chevallier P, Brissot E, Malard F, Guillaume T, Delaunay J, Ayari S, Dubruille V, Le Gouill S, Mahe B, Gastinne T, Blin N, Saulquin B, Harousseau JL, Moreau P, Miplied N, Coste-Burel M, Imbert-Marcille BM, Mohty M. Features of Epstein-Barr Virus (EBV) reactivation after reduced intensity conditioning allogeneic hematopoietic stem cell transplantation. *Leukemia*. 2011 Jun;25(6):932-8. doi: 10.1038/leu.2011.26. Epub 2011 Feb 25. PMID: 21350556.
- 201: Cahu X, Bodet-Milin C, Brissot E, Maisonneuve H, Houot R, Morineau N, Solal-Celigny P, Godmer P, Gastinne T, Moreau P, Moreau A, Lamy T, Kraber-Bodere F, Le Gouill S. 18F-fluorodeoxyglucose-positron emission tomography before, during and after treatment in mature T/NK lymphomas: a study from the GOELAMS group. *Ann Oncol*. 2011 Mar;22(3):705-711. doi: 10.1093/annonc/mdq415. Epub 2010 Aug 25. PMID: 20739714.
- 202: Clavert A, Le Gouill S, Brissot E, Dubruille V, Mahe B, Gastinne T, Blin N, Chevallier P, Guillaume T, Delaunay J, Ayari S, Saulquin B, Moreau A, Moreau P, Harousseau JL, Miplied N, Mohty M. Reduced-intensity conditioning allogeneic stem cell transplant for relapsed or transformed aggressive B-cell non-Hodgkin lymphoma. *Leuk Lymphoma*. 2010 Aug;51(8):1502-8. doi: 10.3109/10428194.2010.497981. PMID: 20583964.
- 203: Malard F, Szydlo RM, Brissot E, Chevallier P, Guillaume T, Delaunay J, Ayari S, Dubruille V, Le Gouill S, Mahe B, Gastinne T, Blin N, Saulquin B, Harousseau JL, Moreau P, Mohty M. Impact of cyclosporine-A concentration on the incidence of severe acute graft-versus-host disease after allogeneic stem cell transplantation. *Biol Blood Marrow Transplant*. 2010 Jan;16(1):28-34. doi: 10.1016/j.bbmt.2009.08.010. Epub 2009 Oct 1. PMID: 20053329.
- 204: Brissot E, Chevallier P, Guillaume T, Delaunay J, Ayari S, Dubruille V, Le Gouill S, Mahe B, Gastinne T, Blin N, Saulquin B, Moreau P, Harousseau JL, Mohty M. Prophylaxis with mycophenolate mofetil and CsA can decrease the incidence of severe acute GVHD after antithymocyte globulin-based reduced-intensity preparative regimen and allo-SCT from HLA-matched unrelated donors. *Bone Marrow Transplant*. 2010 Apr;45(4):786-8. doi: 10.1038/bmt.2009.218. Epub 2009 Aug 31. PMID: 19718059.
- 205: Brissot E, Chevallier P, Guillaume T, Delaunay J, Ayari S, Dubruille V, Le Gouill S, Mahe B, Gastinne T, Blin N, Saulquin B, Flandrois G, Devys A, Stocco V, Cesbron A, Dehaut F, Moreau P, Harousseau JL, Mohty M. Factors predicting allogeneic PBSCs yield after G-CSF treatment in healthy donors. *Bone Marrow Transplant*. 2009 Nov;44(9):613-5. doi: 10.1038/bmt.2009.60. Epub 2009 Mar 23. PMID: 19308036.

Projects

- Member of Société Française d'hématologie (SFH)
- Member of Société Française de Greffe de moëlle et Thérapie cellulaire (SFGM-TC)
- Member of Cryostem
- Associate Editor Current Translational research Medicine
 - 2010 : Prix "jeune chercheur de l'association Laurette Fugain"
 - 2013 : Lauréate Médaille d'or
 - 2013 : Fulbright Study Research Grant
 - 2013 : Prix de la Fondation Phillips
 - 2015 : Prix Boxiao-Fondation de France
 - 2021 : Prix EBMT/Fondation de France- Young Investigator
 - 2021 : Van Bekkum Award (EBMT)
 - 2024: Christian Caillot Clinical Research Award

Memberships

- Member of Société Française d'hématologie (SFH)
- Member of Société Française de Greffe de moëlle et Thérapie cellulaire (SFGM-TC)
- Member of EBMT
- Member au GRAALL

Other Relevant Information